

ISA | 2022

XVIII. INTERNATIONAL SYMPOSIUM
ON AMYLOIDOSIS

4TH – 8TH SEPTEMBER 2022
HEIDELBERG

QUO VADIS
AMYLOIDOSIS?

CONFERENCE
GUIDE





AMYLOIDOSIS CENTER
Heidelberg University Hospital

CLÍNICA
BARCELONA
Hospital Universitari



European Reference Network
for rare or low prevalence complex diseases
Network
Hematological Diseases (ERN EuroBloodNet)



ISA **INTERNATIONAL SOCIETY OF AMYLOIDOSIS**

*Amyloidosis Research and Treatment Center
Foundation «IRCCS Policlinico San Matteo»
Department of Molecular Medicine
University of Pavia
Pavia, Italy*



**UNIVERSITÄT
HEIDELBERG**
ZUKUNFT
SEIT 1386



**UNIVERSITÄTS
KLINIKUM
HEIDELBERG**

CONTENT	03
ORGANIZATION	04
WELCOME ADDRESS	05
GENERAL INFORMATION	06
VENUE	10
FLOORPLAN	12
EXHIBITION PLAN & EXHIBITOR LIST	14
PROGRAM OVERVIEW	16 – 20
DETAILED PROGRAM	22 – 49
SUNDAY, 4 TH	22
MONDAY, 5 TH	23
TUESDAY, 6 TH	31
WEDNESDAY, 7 TH	39
THURSDAY, 8 TH	47
POSTERS	50 – 75
MONDAY, 5 TH	50
TUESDAY, 6 TH	60
WEDNESDAY, 7 TH	68
SPONSORS	76

ORGANIZATION

ISA 2022 Committees

Hosts

Stefan Schönland and Ute Hegenbart,
Amyloidosis Centre, Medical Clinic V,
Medical Faculty of Heidelberg University
Im Neuenheimer Feld 410
69120 Heidelberg

Co-Organizers

Carlos Fernández de Larrea and
Maria Teresa Cibeira, *Barcelona, Spain*
Giovanni Palladini, *Pavia, Italy*

Local Organizing Committee

Markus Weiler and Fabian Siepen
*on behalf of the members of the Amyloidosis
Center, Heidelberg, Germany*

Scientific Advisory Committee Board of International Society of Amyloidosis, ISA

Giovanni Palladini, *President*
Stefan Schönland, *President Elect,
Representative of the German Society*
Yukio Ando, *Past President*
Shaji Kumar, *Treasurer*
Vaishali Sanchorawala, *Secretary*
Per Westermark, *Editor-in-Chief of AMYLOID*
Giampaolo Merlini, *Representative of
the Italian Society*
Ute Hegenbart, *Member at Large*
Paolo Milani, *Member at Large*
Ashutosh Wechalekar, *Member at Large*
Hironobu Naiki, *Representative of the
Japanese Society*

Board of the German Society of Amyloid Diseases, DGAK

Stefan Schönland, *President*
Ute Hegenbart, *Treasurer*
Alexander Carpinteiro, *Secretary*

Organizational Unit

Congress and Conference Management
(UniKT)
Heidelberg University
Seminarstraße 2
69117 Heidelberg

Acknowledgements

We thank Marie Brumma (Amyloidosis
Centre, Medical Clinic V) for her assistance
in all organizational matters and especially
for the intensive sponsor support in
cooperation with UniKT.

We would like to thank our in-house agency
UniKT, which brought the congress from
conception to implementation with the
tireless efforts of the entire team.

We are also grateful to our colleagues who
will be available throughout the conference
to help us manage the many tasks of a
hybrid congress.

Dear all,

On behalf of the International Society of Amyloidosis we want to welcome you to the “XVIII. International Symposium on Amyloidosis” which will be held in the beautiful city center of Heidelberg. Many scientists, philosophers and poets from all over the world have a strong relationship to this unique place. We are proud that the meeting is hosted by the Ruperto Carola University, the one with the longest tradition in Germany, as it was already founded in 1386.



Stefan Schönland
President elect of ISA



Ute Hegenbart
Member of ISA Board

The motto of the XVIII. meeting is “Quo vadis, amyloidosis?” The scientific and clinical developments have been overwhelming in the last years. The general interest is growing as a number of very effective drugs became available in systemic amyloidoses. This is reflected by the scientific program which will feature distinguished keynote speakers, round tables with debates, and compelling presentations by junior scientists as well as established scientists from various fields of amyloidoses. Furthermore, we have created new items like a “best abstracts” session on Thursday. The conference will be held as a hybrid meeting with more than 1100 attendees after the fully virtual conference in 2020.

We heartily thank all the members of the ISA 2022 Committee, the ISA Board and the abstract reviewers for their support in addressing the many challenges of the Corona Pandemic era and the complex circumstances in which we live. We also would like to thank the sponsors for their generous financial support and the organization of industry symposia, as well as the Amyloidosis Foundation, which again provided a large number of grants for young scientists. The winners of the awards will be honored at the Gala Dinner on Wednesday evening in the “halle02”, a former building of the freight depot located in the newest district of Heidelberg named “Bahnstadt”.

We wish you a pleasant and stimulating time with us in Heidelberg, which encompasses academic excellence, cutting-edge medicine, modern urban development and, last but not least, tourist highlights and German Romanticism.

Stefan Schönland and Ute Hegenbart

GENERAL INFORMATION

Abstract Book

The Book of Abstracts and also the Conference Guide can be viewed and downloaded as a flipping book on the conference website.

Badges

Participants receive their conference name badges with their registration material at the conference office or at the booth of the inviting companies and are kindly asked to wear their badges throughout the entire conference. Please use your badge to identify yourself at the external events in the old assembly hall (*Monday*), the inner courtyard of the Triplex Canteen (*Tuesday*) or the Event at halle02 (*Wednesday*).

Certificate of Attendance

You will receive a certificate of attendance with your registration documents.

CME Credits for german attendees

The ISA conference is accredited with CME Credits by the State Chamber of Physicians (Germany). 27 credits are awarded for complete attendance. In order to receive CME Credits for the conference, please contact the registration counter. Corresponding certificates of participation can be picked up at the registration counter after the event.

Coffee Breaks and Lunch

Free coffee and light refreshments will be served during the designated breaks for all participants in the foyers ground floor, second floor and in the courtyard of Neue Universität (New University). Lunch will be available at Triplex Canteen located right next

to Heidelberg University at University Square in the foyer ground floor, in the courtyard of Neue Universität (New University) and Zeughaus Canteen.

Conference office/Registration

The conference office can be found in the foyer of the New University building (Neue Universität; see Floor Plan). Opening hours will be from Sunday 4th September, 14:00 PM to Thursday, 8th September 2:00 PM during the conference hours.

Conference venue

The XVIII. International Symposium on Amyloidosis will take place in the New University building (*Neue Universität*), one of the central buildings of Heidelberg University. It is located at the University Square (*Universitätsplatz*), right in the historic center of Heidelberg city. (*Address: Grabengasse 1, 69117 Heidelberg*)

Copy & Print Service

If you need to copy or print a manageable amount of documents, feel free to contact our staff at the registration desk. For greater print or copy jobs we would also be pleased to refer you to one of the local copy shops in the area.

Getting around

The conference will take place right next to the University Square (*Universitätsplatz*) which is located in the very heart of the historic center of Heidelberg. Starting from there, you can reach many interesting spots within a few minutes' walk (*see Heidelberg Beyond the Conference*).

GENERAL INFORMATION

There are restaurants, hotels and souvenir shops close to the conference venue.

Therefore, you not necessarily have to rely on public transportation in order to get around.

HeidelbergCARD

The HeidelbergCARD offers you free travel on public transport and a one-time entry to the Heidelberg castle courtyard with the barrel cellar and the possibility to visit the German Pharmacy Museum. The HeidelbergCARD also enables several discounts on guided tours, in museums and exhibitions, restaurants as well as on shopping and cultural events. The HeidelbergCARD is available at the conference office.

Internet Access

During the conference all ISA2022 participants have free access to the wireless network of Heidelberg University. Please choose:

Network SSID: **Uni-Webaccess**

User name:

isa00000@webaccess@uni-heidelberg.de

Password: **Z*Kg3oRQdpbd**

If your home institution participates in the eduroam project, you can also use your eduroam network login.

Lunch

The lunch will be offered in three locations. You will receive three vouchers with your registration documents, stating on which day, in which location you will receive your lunch.

a) Triplex Canteen: This is right next to the congress building on the other side of the street. The poster presentations and viewings will also take place here.

b) New University: In the conference building itself.

c) Zeughaus Canteen: In the Marstallhof

d) For all participants dessert will be served in the conference building on the ground floor and on the 2nd floor in front of the main lecture hall.

Pharmacy/Emergency phone numbers

The closest pharmacy, the “Universitäts-Apotheke” is located: Hauptstraße no. 114

opening hours: Mo – Fr, 9:00 AM – 7:00 PM,

Saturday 10:00 AM – 5:00 PM

phone: +49 6221 22 514

Police phone: 110

Fire brigade and medical emergency phone: 112

Ambulance phone: +49 6221 19 222

Public Transportation

In order to get from the conference venue to Heidelberg Central Station or Bismarck Square, please take any bus from “Heidelberg, Universitätsplatz” to “Heidelberg, Bismarckplatz” or “Heidelberg, Hauptbahnhof”.

For detailed timetable and fare information please visit: <http://www.vrn.de>

Tourist information

The tourist information can be found at the ground floor of the Town Hall, within 5 minutes walking distance from the conference venue. (*Address: Marktplatz 10*)

Wheelchair users

The New University building is designed to be wheelchair accessible. Access is via the inner courtyard to the ground floor or via the lift to the upper floors (*see Floor Plan*). If you require assistance, please approach our staff at the Registration Desk.

GENERAL INFORMATION

Heidelberg Beyond the Conference

1. Heiliggeistkirche: The Church of the Holy Spirit was constructed in 1398. Facing the Town Hall, the late Gothic church is located at the Market place (Marktplatz) of Heidelberg and has been both Catholic and Protestant during its long history.

2. Alte Brücke: The famous Old Bridge was erected in 1786 - 1788 by Elector Karl Theodor and consists of barrel vaults of red sandstone.

3. Studentenkärzer & Universitätsmuseum: In the so-called Student Prison students were imprisoned between 1778 and 1914. The university could place students under arrest for up to four weeks.

4. Universitätsbibliothek: The University Library was constructed in 1905 combining elements of German Mannerism of the late 16th century with Art Nouveau motifs. The University Library has over 3 million books, 1.5 million loans each

year and is one of the finest buildings of the university- definitely worth a look.

5. Heidelberger Schloss: Presumably built in between the 13th and 15th century, Heidelberg Castle served as one of the main seats of the Prince Electors of the Palatinate. It was continually enlarged by Ruprecht III and his successors, but destroyed by French troops during the War of Palatine Succession. Even today, the castle ruins still rise majestically over the roofs of the Old Town – one of the absolute must-see sights during a stay in Heidelberg.

6. Philosophenweg: The Philosopher’s Path is one of Germany’s most famous walks. Especially during the Romantic era many poets, famous thinkers and other “children of Heidelberg” – like Hölderlin, Eichendorff and Scheffel, to name a few examples – came here to relax, stroll around, as well as to be inspired by the nature and by the stunning view over the Neckar valley.



© DaLiu, Shutterstock

Special Events

Conference Welcome Reception

Sunday, September 4, 7:00 PM
after the opening lectures
Conference Building Neue Universität

Merlini Award Ceremony

Monday, September 5, 7:05 PM
Building Alte Universität

Get Together with Poster Presentations and Viewing of late breaking abstracts, Challenging Cases and Junior Meets Senior

Tuesday, September 6, 7:00 PM
Triplex Canteen, foyer, 1st floor and courtyard

Award Ceremony, Conference Dinner

Wednesday, September 7, 7:00/7:30 PM
halle02
Zollhofgarten 2, 69115 Heidelberg
How to get there? Please see the information distributed at the congress.

Poster Presentations and Poster Viewings

There are four Poster Viewings between Monday and Wednesday (*see program*). The poster presentations and viewings will take place in the neighbouring building Triplex Canteen on the 1st floor.

Poster Viewing hours:
Monday – Wednesday 11:30 AM – 4:30 PM
Tuesday 6:00 PM – 10:00 PM

The posters will be mounted by the presenters themselves. An assistant will be on site at the following times:

Monday – Wednesday: 7:00 AM – 8:00 AM
and 11:30 AM – 12:00 PM
Tuesday: 6:00 PM – 7:00 PM

Prices and tips

In restaurants, cafes, bars, etc. prices include taxes and service. A tip of approximately 5-10% is appreciated but not obligatory.

Smoking

Due to the strict non-smoking policy with regard to public buildings, smoking is prohibited in all conference venues as well as in most of the restaurants, cafes, etc. Outside the New University building, there are smoking areas and smoking is generally permitted in the street.

Virtual Venue – Venueless

You will find a link to the virtual venue via your Conftool registration access data. Please go to <https://www.conftool.com/isaheidelberg2022/> and login. You will find the link on your Conftool Welcome page.

Wardrobe

There is an unguarded wardrobe in H02 on the ground floor (*see Floor Plan*). Lockers – if necessary – are to be found in the University Library (*Universitätsbibliothek*), just across the road (*about 50 m*).

Additional lecture room H14

The entire program from Main Lecture Hall will be streamed to H14. Exceptions are the few cases when H14 is used for a parallel event.

Getting there

The conference will be held in the "Neue Universität" building which is located in the city center/the Old Town 69117 Heidelberg Germany


AWARD CEREMONY CONFERENCE DINNER Zollhofgarten, halle02

NEUE UNIVERSITÄT

FUNICULAR RAILWAY


CASTLE HEIDELBERG






The conference venue Neue Universität (New University), is a listed building complex in Heidelberg's old town. The New University building was constructed between 1930 and 1934 and was thoroughly modernized between 2009 and 2010. The complex is in the vicinity to Alte Universität (Old University) and Triplex Mensa (Triplex Canteen) where part of the lunch and the poster viewing and presentations (1st floor) as well as the case presentation and Junior meets Senior with Get Together will take place.


FLOORPLAN – GROUND FLOOR



FLOORPLAN – 2ND FLOOR



EXHIBITION FLOORPLAN & EXHIBITOR LIST




GROUND FLOOR

- 3 Life Molecular Imaging
- 4 Amyloidose Alliance
- 4a Myeloma UK
- 5 AbbVie
- 6 Sanofi Aventis
- 7 Alnylam
- 8 Janssen-Cilag
- 9 Attralus
- 11 Binding Site
- 12 Alexion/AstraZeneca
- 15 Sobi™
- 16 Ionis/AstraZeneca UK
- 17 Pfizer
- 18 Bristol Myers Squibb
- 19 GlaxoSmithKline
- 20 International Society of Amyloidosis/
Mayo Clinic
- 21 Protego

EXHIBITION FLOORPLAN & EXHIBITOR LIST

2nd FLOOR

- 1 Ionis/AstraZeneca UK
- 2 Prothena
- 3 BridgeBio
- 4 Alnylam
- 5 Alexion/AstraZeneca
- 6 Pfizer



PROGRAM OVERVIEW – SUNDAY, 4TH

Building opening hours: 8:00 AM – 9:30 PM

4:30 PM – 5:00 PM Neue Aula/Main Lecture Hall
Opening Ceremony

5:00 PM – 7:00 PM Neue Aula/ Main Lecture Hall
Keynote Lecture & Opening Lectures

7:00 PM – 8:00 PM ground floor/2nd floor
Welcome Reception

COLOR CODES

-  **SCIENTIFIC PROGRAM**
-  **POSTER PRESENTATIONS**
-  **SATELLITE SYMPOSIA**
-  **EXHIBITION**
-  **SOCIAL EVENTS**
-  **BREAKS**

Program is subject to changes

PROGRAM OVERVIEW – MONDAY, 5TH

Building opening hours: 7:00 AM – 9:30 PM		
	7:00 AM – 7:45 AM Sponsored breakfast	2nd floor
7:15 AM – 8:30 AM Neue Aula/Main Lecture Hall IKMG/ISA – Challenges in Monoclonal Gammopathy of Renal Significance	7:30 AM – 8:30 AM Global Bridges: Building Diagnostic Capacity Worldwide	H14
8:30 AM – 10:05 AM Neue Aula/Main Lecture Hall Basic research – Light chains including cardiotoxicity OP001 – 008		
10:05 AM – 10:30 AM Virtual Venue Virtual Speaker Corner: Talk with industry partners	10:05 AM – 10:30 AM New University, ground floor/2nd floor/courtyard Coffee Break 	9:30 AM – 5:00 PM ground floor/2nd floor Exhibition on-site and virtual
10:30 AM – 12:05 PM Neue Aula/Main Lecture Hall ATTRwt – Clinical aspects OP009 – 016		
12:05 PM – 1:20 PM Triplex Canteen/1st floor Poster Presentation: AL and ATTR amyloidosis	12:05 PM – 1:20 PM New University, ground floor/courtyard and Triplex Canteen Lunch Break 	
1:20 PM – 3:00 PM Neue Aula/Main Lecture Hall Imaging in amyloidosis OP017 – 024		
3:05 PM – 4:10 PM Neue Aula/Main Lecture Hall Preclinical models of systemic amyloidosis		
	4:10 PM – 4:30 PM New University, ground floor/2nd floor/courtyard Coffee Break 	
4:30 PM – 6:00 PM Neue Aula/Main Lecture Hall Janssen: Navigating the patient journey in AL amyloidosis: a multidisciplinary approach		
6:00 PM – 7:00 PM Neue Aula/Main Lecture Hall Pfizer: How can one solution solve the multifaceted challenges of ATTR amyloidosis?		
7:05 PM – 8:05 PM Alte Aula/Building “Alte Universität” Merlini Award Ceremony		


PROGRAM OVERVIEW – TUESDAY, 6TH

Building opening hours: 7:00 AM – 9:30 PM

7:00 AM – 7:30 AM 2nd floor
Sponsored breakfast

7:30 AM – 8:30 AM Neue Aula/Main Lecture Hall
Prothena: Addressing the Unmet Need in Advanced
AL Amyloidosis: Key Insights from a Panel of Experts

8:30 AM – 10:05 AM Neue Aula/Main Lecture Hall
AL – Clinical aspects OP025 – 032


10:05 AM – 10:30 AM
New University, ground
floor/2nd floor/courtyard
Coffee Break 

9:30 AM – 5:00 PM
ground floor/2nd floor
Exhibition on-site
and virtual

10:30 AM – 12:05 PM Neue Aula/Main Lecture Hall
Basic Research – New treatment targets and biomarkers
OP033 – 040

12:05 PM – 1:15 PM
Triplex Canteen/1st floor
Poster Presentation:
Basic science and imaging

12:05 PM – 1:15 PM
Virtual Venue
Virtual Speaker Corner:
Talk with industry partners

12:05 PM – 1:15 PM
New University, ground floor/
courtyard and Triplex Canteen
Lunch Break 

1:15 PM – 2:30 PM Neue Aula/Main Lecture Hall
AA – Clinical aspects OP041 – 043

2:30 PM – 3:30 PM Neue Aula/Main Lecture Hall
BridgeBio: Improving patient outcomes in ATTR-CM

3:30 PM – 5:00 PM Neue Aula/Main Lecture Hall
Ionis/AstraZeneca: Optimizing Multidisciplinary Care in
Patients With ATTR

5:00 PM – 7:00 PM
Free Time/Explore Heidelberg

Heidelberg

7:00 PM – 7:30 PM Triplex Canteen/1st floor
Poster Presentation: Late breaking abstracts

7:00 PM – 10:00 PM
Get Together
Triplex Canteen/Foyer

7:30 PM – 8:15 PM Triplex Canteen/Foyer
Challenging Cases

8:15 PM – 9:15 PM Triplex Canteen/Foyer
Junior Meets Senior (Round Table)

PROGRAM OVERVIEW – WEDNESDAY, 7TH

Building opening hours: 7:00 AM – 9:30 PM	
7:00 AM – 7:45 AM Sponsored coffee	2nd floor
7:45 AM – 8:30 AM Sobi™: Expert Discussion: Is Disease Remission in hATTR a Realistic Goal?	Neue Aula/Main Lecture Hall
8:30 AM – 10:05 AM ATTRv – Clinical aspects OP044 – 051	Neue Aula/Main Lecture Hall
9:00 AM – 10:00 AM EHA/ISA – Better understanding and targeting the clone in AL amyloidosis	H14
	10:05 AM – 10:30 AM New University, ground floor/2nd floor/courtyard Coffee Break 
10:30 AM – 12:05 PM Pathways to diagnosis OP052 – 059	Neue Aula/Main Lecture Hall
12:05 PM – 1:20 PM Poster Presentation: Pathway to diagnosis, Innovative drugs and non-AL / non-ATTR amyloidosis	Triplex Canteen/1st floor
1:20 PM – 3:00 PM Basic research – Amyloid fibril formation including proteolysis and tissue interactions OP060 – 067	12:05 PM – 1:20 PM New University, ground floor/courtyard and Triplex Canteen Lunch Break 
3:00 PM – 4:30 PM Alexion: Beyond Survival: Unmet Medical Needs in AL Amyloidosis	Neue Aula/Main Lecture Hall
4:30 PM – 5:00 PM Virtual Speaker Corner: Talk with industry partners	Virtual Venue
	4:30 PM – 5:00 PM New University, ground floor/2nd floor/courtyard Coffee Break 
5:00 PM – 6:30 PM Alnylam: Meeting the needs of patients with hATTR amyloidosis: innovation in practice	Neue Aula/Main Lecture Hall
7:00/7:30 PM – open end Conference Dinner/ Award Ceremony	“halle02” Heidelberg

9:30 AM – 5:00 PM
ground floor/2nd floor
Exhibition on-site and virtual


PROGRAM OVERVIEW - THURSDAY, 8TH

Building opening hours: 7:00 AM – 2:00 PM

7:00 AM – 7:45 AM 2nd floor
Sponsored breakfast

7:45 AM – 8:30 AM H14
Attralus: Unmet Need and Rationale for Anti-Amyloid Therapy in Systemic Amyloidosis

8:30 AM – 10:15 AM Neue Aula/Main Lecture Hall
Best abstracts (including late breaking)
OP068 – 071
OPLB001 – 003


10:15 AM – 10:45 AM
New University, ground floor/2nd floor/courtyard
Coffee Break 

9:30 AM – 1:00 PM
ground floor/2nd floor
Exhibition on-site and virtual

10:45 AM – 11:45 AM Neue Aula/Main Lecture Hall
Translation – How to close the gap of basic and clinical research in systemic amyloidosis (Round Table)

11:45 AM – 12:30 PM Neue Aula/Main Lecture Hall
Membership Meeting

12:30 PM – 1:00 PM Neue Aula/Main Lecture Hall
Closing Ceremony

Lunch Boxes 



© Tobias Schwerdt, Heidelberg Marketing

“One thinks Heidelberg by day – with its surroundings – is the last possibility of the beautiful; but when he sees Heidelberg by night, a fallen Milky Way, with that glittering railway constellation pinned to the border, he requires time to consider upon the verdict.”

Mark Twain

DETAILED PROGRAM

SUNDAY, 4TH –
THURSDAY, 8TH

DETAILED PROGRAM – SUNDAY, 4TH

4:30 PM – 5:00 PM	SOCIAL EVENT	Neue Aula/Main Lecture Hall
	Opening Ceremony Musical accompaniment Kathrin Christians, <i>Flute</i> , Sonia Akchar, <i>Piano</i>	
	<i>Ute Hegenbart, host ISA 2022, Amyloidosis Center of the University Hospital, Heidelberg, Germany</i> <i>Giovanni Palladini, ISA president, Amyloidosis Research and Treatment Center, University of Pavia and IRCCS Fondazione Policlinico San Matteo, Pavia, Italy</i> <i>Christian Schaaf, Representative of the Center of Rare Diseases, University Hospital, Heidelberg, Germany</i>	
5:00 PM – 7:00 PM	SCIENTIFIC SESSION	Neue Aula/Main Lecture Hall
	Keynote Lecture & Opening Lectures	
Chairs	<i>Stefan Schönland, host ISA 2022, Amyloidosis Center of the University Hospital, Heidelberg, Germany</i> <i>Giovanni Palladini, ISA president, Amyloidosis Research and Treatment Center, University of Pavia and IRCCS Fondazione Policlinico San Matteo, Pavia, Italy</i>	
Introduction	Stefan Schönland	
Keynote Lecture	Aging (of the Immune System) <i>Cornelia Weyand, Stanford University, Stanford, and Mayo Clinic, Rochester, USA</i>	
Opening Lecture	AL Amyloidosis model – leading the way to cure <i>Giampaolo Merlini, Amyloidosis Research and Treatment Center, University of Pavia and IRCCS Fondazione Policlinico San Matteo, Pavia, Italy</i>	
Introduction	Giovanni Palladini	
Opening Lectures	Turning swords into plowshares: the case of functional amyloid <i>Daniel Otzen, Aarhus University, Aarhus, Denmark</i> New horizons of gene targeting therapy in ATTRv amyloidosis <i>Julian Gillmore, National Amyloidosis Centre, London, United Kingdom</i>	
7:00 PM – 8:00 PM	SOCIAL EVENT	ground floor/2nd floor
	Welcome Reception Get Together with served snacks and beverages	

DETAILED PROGRAM – MONDAY, 5TH

9:30 AM – 5:00 PM **EXHIBITION** ground floor/2nd floor
Exhibition on-site and virtual

7:30 AM – 8:30 AM **SATELLITE SYMPOSIUM** H14
Sponsored breakfast starts at 7:00 AM

Global Bridges: Building Diagnostic Capacity Worldwide
Amyloidosis Grantee Presentations

Chairs Morie Gertz, *Mayo Clinic, Rochester, USA*
Martha Grogan, *Mayo Clinic, Rochester, USA*

Introduction Morie Gertz
Presentations **Building Awareness and Improving the Quality of Diagnosis**
Sharmila Dorbala, *Brigham and Women's Hospital, USA*
Firas Al Badarin, *Cleveland Clinic Abu Dhabi, UAE*
Bruno Bueno, *Heart Institute, Hospital Das Clinicas, U Sao Paulo, Brazil*
Isabel Carvajal Juárez, *ASNC Latin America, Mexico*
Special patient populations/leveraging technology
Saurabh Malhotra, *Cook County Health, Illinois, USA*
Paolo Milani, *Amyloid Research and Treatment Center, IRCCS
Fondazione Policlinico San Matteo, Pavia, Italy*
Establishing Regional Centers of Excellence
Ramzi Tabbalat, *Abdali Medical Center, Jordan*
Silvia Lupu, *Emergency Institute for Cardiovascular Disease and
Transplant, Romania*
Kwaku Appiah-Kubi, *C.K. Tedam University of Technology and Applied
Science, Ghana*
Summary/Close Martha Grogan

7:15 AM – 8:30 AM **SCIENTIFIC SESSION** Neue Aula/Main Lecture Hall
**IKMG/ISA – Challenges in Monoclonal Gammopathy of Renal
Significance**
Joint Session

Chairs Ute Hegenbart, *host ISA 2022, Amyloidosis Center of the University
Hospital, Heidelberg, Germany*
Nelson Leung, *Mayo Clinic, Rochester, USA*

DETAILED PROGRAM – MONDAY, 5TH

- Lectures
- Differential diagnosis of MGRS
Guillermo Herrera, *University of South Alabama, USA*
- Treatment endpoints in MGRS
Angela Dispenzieri, *Mayo Clinic, Rochester, USA*
- MGRS: directions for future research
Frank Bridoux, *Hôpital Jean Bernard, Poitiers, France*
-


8:30 AM – 10:05 AM **SCIENTIFIC SESSION** Neue Aula/Main Lecture Hall
Basic research – light chains including cardiotoxicity

- Chairs
- Stefano Ricagno, *Università di Milano, Milano, Italy*
Marina Ramirez-Alvarado, *Mayo Clinic, Rochester, USA*

State-of-the-art lecture Stefano Ricagno

- OP001 **Next Generation Sequencing Identifies AL-related IGLV Genes in Patients with λ -isotype MGUS or Smoldering Multiple Myeloma**
Ray Comenzo, *Tufts Medical Center, Boston, USA*
- OP002 **Elucidation of the cardiotoxicity of full-length light chains derived from patients with cardiac light chain amyloidosis in comparison to other plasma cell dyscrasias**
Panagiota-Efstathia Nikolaou, *National and Kapodistrian University, Athens, Greece*
- OP003 **Investigation of IGLV2-14 AL amyloidosis and multiple myeloma light chain sequences**
Natalie Berghaus, *Amyloidosis Center of the University Hospital, Heidelberg, Germany*
- OP004 **Sequence diversity of the kappa light chains from patients with AL amyloidosis and multiple myeloma**
Sarah Schreiner, *Amyloidosis Center of the University Hospital, Heidelberg, Germany*
- OP005 **Single Molecule Real-Time Sequencing of the M protein (SMaRT M-Seq): toward personalized medicine approaches in monoclonal gammopathies**
Mario Nuvolone, *Amyloidosis Research and Treatment Center, University of Pavia and IRCCS Fondazione Policlinico San Matteo, Pavia, Italy*
- OP006 **An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis**
Alice Nevone, *Amyloidosis Research and Treatment Center, University of Pavia and IRCCS Fondazione Policlinico San Matteo, Pavia, Italy*

DETAILED PROGRAM – MONDAY, 5TH

- OP007 Amyloidogenesis by mesangial cells involves active participation of lysosomes
Guillermo A. Herrera, *University of South Alabama, Alabama, USA*
- OP008 Mapping and modelling the molecular mechanisms that drive amyloidogenic light chain induced cardiotoxicity
Camille Vanessa Edwards, *Boston University, Boston, USA*
-
- 10:05 AM – 10:30 AM **COFFEE BREAK**  New University, ground floor/2nd floor/courtyard
-
- 10:05 AM – 10:30 AM **EXHIBITION** Virtual Venue
Virtual Speaker Corner
Talk with industry partners
-
- 10:30 AM -12:05 PM **SCIENTIFIC SESSION** Neue Aula/Main Lecture Hall
ATTRwt – Clinical aspects
- Chairs: Thibaud Damy, *Referral Center for Cardiac Amyloidois, Henri Mondor Hospital, Creteil, France*
Matthew Maurer, *Columbia University, New York, USA*
- State-of-the-art lecture Thibaud Damy
- OP009 Long-term tafamidis treatment reduces the decline in quality of life among patients with transthyretin amyloid cardiomyopathy
Martha Grogan, *Mayo Clinic, Rochester, USA*
- OP010 Atrial fibrillation as a prognostic factor for all-cause mortality in patients with transthyretin amyloid cardiomyopathy
Ronald Witteles, *Stanford University, Stanford, USA*
- OP011 Long-term safety and tolerability of acoramidis (AG10) in symptomatic transthyretin amyloid cardiomyopathy: Updated analysis from an ongoing phase 2 open-label extension study
Ahmad Masri, *OHSU, Portland, USA*
- OP012 Chronic Intravenous Inotropic Therapy in Cardiac Amyloidosis
Johana Rocio Fajardo, *Medstar Heart & Vascular Institute, Washington, USA*
- OP013 Tolerability and side-effects of therapy in an open-label trial of inotersen for transthyretin amyloid cardiomyopathy
Leo C. Samuels, *Brigham and Women's Hospital, Boston, USA*

DETAILED PROGRAM – MONDAY, 5TH

Chairs **ATTRv amyloidosis**
Ernst Hund, *Amyloidosis Center of the University Hospital, Heidelberg, Germany*
Katrin Hahn, *Amyloidosis Center, Charité, Berlin, Germany*
Isabel Maria Conceicao, *Centro Hospitalar Universitário Lisboa Norte – Hospital de Santa Maria, Lisboa, Portugal*
Markus Weiler, *Amyloidosis Center of the University Hospital, Heidelberg, Germany*

1:20 PM – 3:00 PM

SCIENTIFIC SESSION

Neue Aula/Main Lecture Hall

Imaging in amyloidosis

Chairs Ashutosh Wechalekar, *National Amyloidosis Centre, London, United Kingdom*
Sharmila Dorbala, *Brigham and Women's Hospital, Boston, USA*

State-of-the-art lecture **Amyloid Imaging**
Ashutosh Wechalekar

State-of-the-art lecture **Cardiac Imaging**
Sharmila Dorbala

OP017 **Results of the first-in-human PET/CT imaging study of the amyloid-reactive peptide 124I-AT-01 (124I-p5+14) for the detection of systemic amyloidosis**
Jonathan Wall, *University of Tennessee, Knoxville, USA*

OP018 **Pan-amyloid reactivity of radioiodinated peptide 124I-AT-01 in patients with systemic amyloidosis demonstrated by PET/CT imaging**
Emily Martin, *University of Tennessee, Knoxville, USA*

OP019 **Tracking multi-organ treatment response in systemic AL-amyloidosis with cardiac magnetic resonance derived extracellular volume mapping**
Adam Ioannou, *Royal Free Hospital, London, United Kingdom*

OP020 **Regression of Cardiac Bone-Tracer Uptake in Patients with Hereditary Transthyretin Amyloidosis after One Year Treatment with Patisiran. An early Marker of Treatment Response?**

Hendrea S.A. Tingen, *University Medical Center, Groningen, Netherlands*

OP021 **Real World Experience of Tc-DPD scintigraphy as a diagnostic imaging tool in amyloidosis**
Muhammad Umaid Rauf, *National Amyloidosis Centre, London, United Kingdom*

DETAILED PROGRAM – MONDAY, 5TH

- OP022 Assessing left ventricular strain in cardiac amyloidosis:
the importance of accurate measurement technique
Rodney H. Falk, *Brigham and Women's Hospital, Boston, USA*
- OP023 Quantitative magnetic resonance neurography biomarkers: Cross-
sectional results from a single center study in 80 subjects with
symptomatic or asymptomatic hereditary transthyretin amyloidosis
Jennifer Hayes, *Amyloidosis Center of the University Hospital, Heidelberg*
- OP024 Assessment of the clinical value of whole-body MRI in untreated
patients with systemic light chain amyloidosis
Simone Christine Brandelik, *Amyloidosis Center of the University
Hospital, Heidelberg, Germany*
-

3:05 PM – 4:10 PM **SCIENTIFIC SESSION** Neue Aula/Main Lecture Hall
Preclinical models of systemic amyloidosis

Chairs Alexander Carpinteiro, *Amyloidosis Center of the University Hospital,
Essen, Germany*
Gunilla Westermark, *Uppsala University, Uppsala, Sweden*

Introduction Alexander Carpinteiro
Lectures **A mouse model of AL amyloidosis**
Christophe Sirac, University of Limoges, Limoges, France
Insights into ATTR amyloidosis from a new transgenic mouse model
Paul Simons, National Amyloidosis Centre, London, United Kingdom
AL amyloidosis modelled in *Caenorhabditis elegans*
Luisa Diomedede, Mario Negri IRCCS, Milano, Italy

Debate Christophe Sirac, Paul Simons, Luisa Diomedede

4:10 PM – 4:30 PM **COFFEE BREAK**  New University, ground floor/2nd floor/courtyard

4:30 PM – 6:00 PM **SATELLITE SYMPOSIUM** Neue Aula/Main Lecture Hall
**Janssen: Navigating the patient journey in AL amyloidosis:
a multidisciplinary approach**

Chairs Giovanni Palladini, *Amyloidosis Research and Treatment Center, Univer-
sity of Pavia and IRCCS Fondazione Policlinico San Matteo, Pavia, Italy*
Marianna Fontana, *National Amyloidosis Centre, London, United
Kingdom*

DETAILED PROGRAM – MONDAY, 5TH

Introduction	Giovanni Palladini
Lecture	Diagnostic pit-falls and risk stratification in AL amyloidosis Marianna Fontana
Panel Discussion	Frank Bridoux, <i>Hôpital Jean Bernard, Poitiers, France</i> Darren Foard, <i>National Amyloidosis Centre, London, United Kingdom</i> Christoph Röcken, <i>University Hospital, Kiel, German</i>
Lecture	Key considerations when selecting treatment for patients with AL amyloidosis Giovanni Palladini
Panel Discussion	Frank Bridoux, Darren Foard, Christoph Röcken
Summary/Close	Giovanni Palladini
<hr/>	
6:00 PM – 7:00 PM	SATELLITE SYMPOSIUM Neue Aula/Main Lecture Hall Pfizer: How can one solution solve the multifaceted challenges of ATTR amyloidosis?
Chairs	Arnt Kristen, <i>Amyloidosis Center of the University Hospital, Heidelberg, Germany</i>
Introduction	Arnt Kristen
Lectures	Transthyretin in health and disease Laura Obici, <i>Amyloidosis Research and Treatment Center, University of Pavia and IRCCS Fondazione Policlinico San Matteo, Pavia, Italy</i> Improving patient outcomes in ATTR-PN Laura Obici Addressing cardiac involvement in patients with ATTR amyloidosis Arnt Kristen Clinical clues to cardiac involvement in ATTR amyloidosis – how to identify patients early Arnt Kristen, Rachele Bonfiglioli, <i>Azienda Ospedaliero-Universitaria, Bologna, Italy</i>
Panel Discussion/Close	Arnt Kristen, Laura Obici, Rachele Bonfiglioli

DETAILED PROGRAM – MONDAY, 5TH

7:05 PM – 8:05 PM

SOCIAL EVENT

Alte Aula/Building “Alte Universität”

Merlini Award Ceremony

Musical accompaniment

Kathrin Christians, *Flute*, Sonia Akchar, *Piano*

Laudatio

Giovanni Palladini, *Amyloidosis Research and Treatment Center, University of Pavia and IRCCS Fondazione Policlinico San Matteo, Pavia, Italy*

Lecture

Amyloidosis: Reflections on passed and coming times

Per Westermark, *University Hospital, Uppsala, Sweden*

Merlini Award Winner 2022



DETAILED PROGRAM – TUESDAY, 6TH

9:30 AM – 5:00 PM **EXHIBITION** ground floor/2nd floor
Exhibition on-site and virtual

7:30 AM – 8:30 AM **SATELLITE SYMPOSIUM** Neue Aula/ Main Lecture Hall
Sponsored breakfast starts at 7:00 AM

**Prothena: Addressing the Unmet Need in Advanced AL Amyloidosis:
Key Insights from a Panel of Experts**

Chair Morie Gertz, *Mayo Clinic, Rochester, USA*

Introduction Morie Gertz

Lectures **Epidemiology and Unmet Need in Advanced AL Amyloidosis**
Maria Papathanasiou, University Hospital Essen, Germany
Diagnosis and Current Treatment Approaches in AL Amyloidosis
Giovanni Palladini, Amyloidosis Research and Treatment Center, University of Pavia and IRCCS Fondazione Policlinico San Matteo, Pavia, Italy
Emerging Therapies in Advanced AL Amyloidosis
Morie Gertz

Panel Discussion Morie Gertz, Maria Papathanasiou, Giovanni Palladini

8:30 AM – 10:05 AM **SCIENTIFIC SESSION** Neue Aula/Main Lecture Hall
AL – Clinical aspects

Chairs Shaji Kumar, *Mayo Clinic, Rochester, Minnesota, USA*
Vaishali Sanchorawala, *Amyloidosis Center at Boston University School of Medicine, Boston, USA*

State-of-the-art lecture Shaji Kumar
OP025 **Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: a 25-year longitudinal study**
Joshua Gustine, Amyloidosis Center at Boston University School of Medicine, Boston, USA

OP026 **The prognostic importance of flow cytometry-based measurable residual disease (MRD) in patients with systemic light chain amyloidosis**
Andrew Staron, Amyloidosis Center at Boston University School of Medicine, Boston, USA

DETAILED PROGRAM – TUESDAY, 6TH

- OP027 Prognostic Impact of Translocation t(11;14) and of other cytogenetic abnormalities in patients with AL amyloidosis in the era of contemporary therapies
Despina Fotiou, National and Kapodistrian University, Athens, Greece
- OP028 Incidence and risk factors of sudden death in patients with cardiac amyloidosis
Fernando de Frutos, Hospital Universitario Puerta de Hierro, Majadahonda, Spain
- OP029 Clonal features affect survival of patients with non-cardiac light chain (AL) amyloidosis: a European study of 386 patients
Paolo Milani, Amyloid Research and Treatment Center, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy
- OP030 Light chain deposition disease: an international study in 523 patients
Paolo Milani, Amyloidosis Research and Treatment Center, University of Pavia and IRCCS Fondazione Policlinico San Matteo, Pavia, Italy
- OP031 Elotuzumab in combination with IMiDs for AL amyloidosis patients with relapsed/refractory plasma cell dyscrasia and advanced organ involvement
Tobias Dittrich, Amyloidosis Center of the University Hospital, Heidelberg, Germany
- OP032 First Report on Outcome of Patients with Newly Diagnosed Stage IIIb Cardiac Light Chain Amyloidosis Treated with Daratumumab-based Frontline Therapy
Rajshekhkar Chakraborty, Irving Medical Center, Columbia, USA

10:05 AM – 10:30 AM **COFFEE BREAK**  New University, ground floor/2nd floor/courtyard

10:30 AM – 12:05 PM **SCIENTIFIC SESSION** Neue Aula/Main Lecture Hall
Basic Research – New treatment targets and biomarkers

Chairs *Gareth Morgan, Amyloidosis Center at Boston University School of Medicine, Boston, USA*
Carlos Fernández de Larrea, Amyloidosis and Myeloma Unit, Barcelona, Spain

DETAILED PROGRAM – TUESDAY, 6TH

- State-of-the-art lecture Gareth Morgan
- OP033 Collagen associated with AL amyloid inhibits fibril phagocytosis - Collagen degradation renders amyloid sensitive to uptake by the innate immune system
Joseph W. Jackson, University of Tennessee, Knoxville, USA
- OP034 In-vitro ultrasonic assay indicates importance of extracellular chaperon-like effect of serum albumin to protect dialysis patients from dialysis-related amyloidosis
Kichitaro Nakajima, Osaka University, Osaka, Japan
- OP035 Dissecting FAM46C-dependent tuning of antibody secretion in systemic AL amyloidosis
Enrico Milan, San Raffaele Scientific Institute, Milano, Italy
- OP036 Development of novel human chimeric antigen receptor-macrophages (CAR-M) as a potential therapeutic for amyloid clearance
Manasi Balachandran, University of Tennessee, Knoxville, USA
- OP037 Preclinical characterization of AT-02, a pan-amyloid-binding immunoglobulin-peptide fusion protein capable of inducing enhanced phagocytosis of amyloid
Jonathan Wall, University of Tennessee, Knoxville, USA
- OP038 Regulation of BCL2 family members by microRNA-9 and microRNA-181a in AL amyloidosis
Oshrat Hershkovitz-Rokah, Assuta Medical Center, Tel Aviv, Israel
- OP065 AA amyloid-containing diet potentiates A β 42 induced effects in transgenic *Drosophila melanogaster*
Gunilla Westermark, Uppsala University, Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden
- OP040 Targeting protein secretion as a therapeutic strategy in AL amyloidosis
Maria Moscvin, Brigham and Women's Hospital, Boston, USA

12:05 PM – 1:15 PM

LUNCH



New University, ground floor/courtyard & Triplex Canteen

DETAILED PROGRAM – TUESDAY, 6TH

12:05 PM – 1:15 PM	POSTER PRESENTATIONS	Triplex Canteen, 1st floor
	Poster Numbers: P122 – P190: Basic science and Imaging For the virtual audience the poster and an audio summary by the presenting authors will be provided in the Virtual Venue.	
Chairs	Fibril and Amyloid Formation Mario Nuvolone, <i>Amyloidosis Research and Treatment Center, University of Pavia and IRCCS Fondazione Policlinico San Matteo, Pavia, Italy</i> Christoph Röcken, <i>University Hospital, Kiel, Germany</i> Joost Schymkowitz, <i>Leuven Center for Brain & Disease Research, Leuven, Belgium</i>	
Chairs	Mechanism of organ dysfunction and damage Marina Ramirez-Alvarado, <i>Mayo Clinic, Rochester, USA</i> Stefano Ricagno, <i>Università di Milano, Milano, Italy</i>	
Chairs	Pre-clinical disease models Gunilla Westermark, <i>Uppsala University, Uppsala, Sweden</i> Alexander Carpinteiro, <i>University Hospital Essen, Germany</i>	
Chairs	Imaging Simon Gibbs, <i>The Victorian and Tasmanian Amyloidosis Service, Australian Amyloidosis Network, Australia</i> Jennifer Hayes, <i>Amyloidosis Center of the University Hospital, Heidelberg, Germany</i> Jonathan Wall, <i>University of Tennessee, Knoxville, USA</i> Martha Grogan, <i>Mayo Clinic, Rochester, USA</i>	

12:05 PM – 1:15 PM	EXHIBITION	Virtual Venue
	Virtual Speaker Corner Talk with industry partners	

DETAILED PROGRAM – TUESDAY, 6TH

1:15 PM – 2:30 PM **SCIENTIFIC SESSION** Neue Aula/Main Lecture Hall
AA – Clinical aspects

Chairs Norbert Blank, *Amyloidosis Center of the University Hospital, Heidelberg, Germany*
Sophie Geogin-Lavialle, *Sorbonne University, Paris, France*

State-of-the-art lecture Norbert Blank

Lectures **AA Amyloidosis in Europe, Perspectives and Challenges**
Sophie Geogin-Lavialle

AA Amyloidosis in Africa, Perspectives and Challenges
Ghalia Khellaf, *Centre Hospitalo-Universitaire, Alger, Algeria*

OP041 **Tocilizumab can prevent the progression of renal AA amyloidosis to end stage renal disease**
Peter Kvacsakay, *Amyloidosis Center of the University Hospital, Heidelberg, Germany*

OP042 **Natural history and risk stratification of AA amyloidosis based on a 40-year experience in the United States**
Tracy Joshi, *Amyloidosis Center at Boston University School of Medicine, Boston, USA*

OP043 **Long-term transplant outcomes in recipients with renal amyloidosis**
Tale Norbye Wien, *Bærum Hospital Vestre Viken, Drammen, Norway*

2:30 PM – 3:30 PM **SATELLITE SYMPOSIUM** Neue Aula/Main Lecture Hall
BridgeBio: Improving patient outcomes in ATTR-CM

Chairs Julian Gillmore, *National Amyloidosis Centre, London, United Kingdom*
Matthew S. Maurer, *Columbia University, New York, USA*

Introduction Julian Gillmore, Mathew S. Maurer

Lectures **ATTR-CM consensus – what's new?**
Claudio Rapezzi, *University of Ferrara, Ferrara, Italy*

Present and future in ATTR-CM
Pablo Garcia-Pavia, *Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain*

Q&A/Close Julian Gillmore, Mathew S. Maurer

DETAILED PROGRAM – TUESDAY, 6TH

3:30 PM – 5:00 PM	SATELLITE SYMPOSIUM	Neue Aula/Main Lecture Hall
	Ionis/AstraZeneca: Optimizing Multidisciplinary Care in Patients With ATTR	
Chair	Arnt Kristen, <i>Amyloidosis Center of the University Hospital, Heidelberg, Germany</i>	
Introduction	Arnt Kristen	
Patient Journey Video	Arnt Kristen	
	ATTR: Disease Overview	
	Arnt Kristen	
Lecture	Optimizing Patient Care: A Neurologist's Perspective <i>Teresa Coelho, Centro Hospitalar Universitário, Porto, Portugal</i>	
	Interactive Case Studies: Neurology	
Panel Discussion	Arnt Kristen, Teresa Coelho, <i>Pablo Garcia-Pavia, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain</i>	
Lecture	Optimizing Patient Care: A Cardiologist's Perspective Pablo Garcia-Pavia	
	Interactive Case Studies: Cardiology	
Panel Discussion/Q&A	Arnt Kristen, Teresa Coelho, Pablo Garcia-Pavia	
Close	Arnt Kristen	

5:00 PM – 7:00 PM		Heidelberg
	Free Time/Explore Heidelberg	
	We have posted some nice options for sightseeing and leisure tours on our ISA 2022 homepage.	

DETAILED PROGRAM – TUESDAY, 6TH

7:00 PM – 10:00 PM **SOCIAL EVENT** Triplex Canteen Foyer/1st floor/Courtyard
Get Together
Get Together with served snacks and beverages

07:00 PM – 07:30 PM **POSTER PRESENTATIONS** Triplex Canteen, 1st floor
Poster Numbers: PLB001 – 017: Late breaking abstracts
For the virtual audience the poster and an audio summary by the presenting authors will be provided in the Virtual Venue.

Chairs Suzanne Lentzsch, *Columbia University, New York, USA*
Per Westermark, *Uppsala University, Uppsala, Sweden*

7:30 PM – 8:15 PM **SCIENTIFIC SESSION** Triplex Canteen, Foyer
Challenging Cases
Three cases of diagnostic and therapeutic challenges will be presented during this session. Panelists and audience will participate to solve these difficult cases.

Chairs Vaishali Sanchorawala, *Amyloidosis Center at Boston University School of Medicine, Boston, USA*
Maite Cibeira, *Amyloidosis and Myeloma Unit, Barcelona, Spain*
Paolo Milani, *Amyloidosis Research and Treatment Center, University of Pavia and IRCCS Fondazione Policlinico San Matteo, Pavia, Italy*

Panel of Experts Angela Dispenzieri, *Mayo Clinic, Rochester, USA*
Julian Gillmore, *National Amyloidosis Centre, London, United Kingdom*
Pablo Garcia-Pavia, *Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain*

DETAILED PROGRAM – TUESDAY, 6TH

8:15 PM – 9:15 PM

SOCIAL EVENT

Triplex Canteen, Foyer

Junior Meets Senior Round Table

The path of a scientific career is often long and sometimes difficult. The goal of this session is to provide junior physicians and scientists in the audience a chance to interact with experts in the field of Amyloidosis and beyond. Both, young and established colleagues might profit from sharing their experience in diverse areas, including their academic careers, approach to research and publishing, and also more personal aspects like work-life balance.

Chairs

Fabian aus dem Siepen, *Amyloidosis Center of the University Hospital, Heidelberg, Germany*
Eloisa Riva, *Hospital de Clínicas “Dr. Manuel Quintela”, Montevideo, Uruguay*

Senior Experts

Per Westermark, *Uppsala University, Uppsala, Sweden*
Suzanne Lentzsch, *Columbia University, New York, USA*
Cornelia Weyand, *Stanford University, Stanford, and Mayo Clinic, Rochester, USA*
Jörg Goronzy, *Stanford University, Stanford and Mayo Clinic, Rochester, USA*
Martha Grogan, *Mayo Clinic, Rochester, USA*
Carsten Müller-Tidow, *University Hospital, Heidelberg, Germany*
Norbert Frey, *University Hospital, Heidelberg, Germany*



DETAILED PROGRAM – WEDNESDAY, 7TH

9:30 AM – 5:00 PM **EXHIBITION** ground floor/2nd floor
Exhibition on-site and virtual

7:45 AM – 8:30 AM **SATELLITE SYMPOSIUM** Neue Aula/Main Lecture Hall
Sponsored coffee starts at 7:00 AM

Sobi™: Expert Discussion: Is Disease Remission in hATTR a Realistic Goal?

Chair Teresa Coelho, *Centro Hospitalar Universitário, Porto, Portugal*

Introduction Teresa Coelho

Lectures **Evolution of diagnosis and management of hATTR**
Katrin Hahn, *Amyloidosis Center, Charité, Berlin, Germany*

“Flipping the pyramid”: lessons learned from MS
Gavin Giovannoni, *Queen Mary University, London, United Kingdom*
Are we primed to make remission a reality?

Marco Luigetti, *Università Cattolica del Sacro Cuore, Rome, Italy*

Panel Discussion Teresa Coelho, Katrin Hahn, Gavin Giovannoni, Marco Luigetti

Conclusion Teresa Coelho

8:30 AM – 10:05 AM **SCIENTIFIC SESSION** Neue Aula/Main Lecture Hall
ATTRv – Clinical aspects

Chairs David Adams, *Université Paris Saclay, Paris, France*
Marcia Waddington-Cruz, *Federal University of Rio de Janeiro, Rio de Janeiro, Brazil*

State-of-the-art lecture David Adams
OP044 **Patisiran Global Open-label Extension Study at 36 Months: Effect of Long-term Treatment on Mortality and Ambulatory Function in Patients with hATTR Amyloidosis with Polyneuropathy**

Jonas Wixner, *Umeå University, Umeå, Sweden*

OP045 **Progression and distribution pattern of cerebral amyloid angiopathy in hereditary ATTR amyloidosis patients visualized by 11C-PiB-PET imaging**

Yusuke Takahashi, *Shinshu University, Matsumoto, Japan*

DETAILED PROGRAM – WEDNESDAY, 7TH

- OP046 An international Delphi survey for the definition of a multidisciplinary holistic approach to the care of hereditary ATTR amyloidosis
Laura Obici, Amyloidosis Research and Treatment Center, University of Pavia and IRCCS Fondazione Policlinico San Matteo, Pavia, Italy
- OP047 Eplontersen in ATTR-polyneuropathy: results from the 35-week interim analysis of NEURO-TTRransform
Teresa Coelho, Centro Hospitalar Universitário, Porto, Portugal
- OP048 Diflunisal treatment for hereditary transthyretin amyloidosis – the Swedish DFNS-02 trial
Jonas Wixner, Umeå University, Umeå, Sweden
- OP049 Kidney phenotype and immune activation in hereditary ATTR amyloidosis during inotersen therapy
Joana Tavares, Centro Hospitalar Universitário do Porto, Porto, Portugal
- OP050 Association of hereditary V122I amyloidogenic transthyretin variant with heart failure: A systematic review and meta-analysis
Kwaku Appiah-Kubi, C. K. Tedam University, Navrongo, Ghana
- OP051 Tafamidis reduces skin denervation and amyloid in skin biopsies of very early symptomatic hATTRv patients after one year of treatment
Alejandra Gonzalez-Duarte, INCMNSZ, Ciudad de México, Mexico

9:00 AM – 10:00 AM

SCIENTIFIC SESSION

H14

EHA/ISA – Better understanding and targeting the clone in AL amyloidosis

Chairs

Efstathios Kastritis, National and Kapodistrian University, Athens, Greece

Monique Minnema, University Medical Center, Utrecht, Netherlands

Lectures

Future Myeloma therapies suitable for AL amyloidosis

Marc Raab, Myeloma Center, University Heidelberg, Germany

Marginal zone lymphoma and M. Waldenström as underlying disease in AL amyloidosis

Davide Rossi, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

10:05 AM – 10:30 AM

COFFEE BREAK



New University, ground floor/2nd floor/courtyard

DETAILED PROGRAM – WEDNESDAY, 7TH

10:30 AM – 12:05 PM

SCIENTIFIC SESSION

Neue Aula/Main Lecture Hall

Pathways to diagnosis

Chairs

Hironobu Naiki, *University of Fukui, Fukui, Japan*

Kerstin Amann, *University Hospital, Erlangen, Germany*

State-of-the-art lecture

Hironobu Naiki

OP052

Automated cardiac amyloidosis risk detection on whole body bone scintigraphy using deep-learning approach

Marc-Antoine Delbarre, *University Hospital, Amiens, France*

OP053

Establishment of the nation-wide pathology consultation system for the typing diagnosis of amyloidosis in Japan: Steep increase in the number of transthyretin-positive cardiac biopsy cases

Hironobu Naiki

OP054

The amyloid proteome: a two-way approach for a protein classification system

Juliane Gottwald, *University Hospital, Kiel, Germany*

OP055

Fat aspiration as a screening tool for symptomatic systemic amyloidosis - sensitivity and specificity analysis with better sensitivity results for females with all major subtypes

Christoph Richard Kimmich, *University Hospital, Oldenburg, Germany*

OP056

Sequence of diagnostic testing in cardiac amyloidosis patients: early monoclonal protein study is associated with better outcomes in AL amyloidosis

Francesca Fabris, *Amyloid Research and Treatment Center, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy*

OP057

Artificial intelligence modeling for earlier identification of cardiac amyloidosis

Surendra Dasari, *Mayo Clinic, Rochester, USA*

OP058

A novel mass spectrometry-based method for the identification of subtype specific amyloidogenic proteins from fat aspirates

Hans Christian Beck, *University Hospital, Odense, Denmark*

OP059

Pre-symptomatic diagnosis of systemic AL amyloidosis by biomarker-based screening in patients with MGUS

Silvia Mangiacavalli, *Amyloid Research and Treatment Center, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy*

DETAILED PROGRAM – WEDNESDAY, 7TH

12:05 PM – 1:20 PM **LUNCH**  New University, ground floor/courtyard & Triplex Canteen

12:05 PM – 1:20 PM **POSTER PRESENTATIONS** Triplex Canteen, 1st floor

Poster Numbers: P191 – P295 (except P208, moved to Monday):

**Pathway to diagnosis, Innovative drugs and non-AL/
non-ATTR amyloidosis**

For the virtual audience the poster and an audio summary by the presenting authors will be provided in the Virtual Venue.

Pathway to Diagnosis

Chairs

Eli Muchtar, *Mayo Clinic, Rochester, USA*

Rahel Schwotzer, *University Hospital, Zurich, Switzerland*

Fabian aus dem Siepen, *Amyloidosis Center of the University Hospital, Heidelberg, Germany*

Eloisa Riva, *Hospital de Clínicas “Dr. Manuel Quintela”, Montevideo, Uruguay*

Sandra Ihne, *Amyloidosis Center, University Hospital Würzburg, Germany*

Hans Nienhuis, *Amyloidosis Centre of Expertise, University Medical Center, Groningen, Netherlands*

Kerstin Amann, *University Hospital, Erlangen, Germany*

Hironobu Naiki, *University of Fukui, Fukui, Japan*

Arnaud Jaccard, *CHU, Limoges, France*

AA Amyloidosis

Chair

Norbert Blank, *Amyloidosis Center of the University Hospital, Heidelberg, Germany*

Biology, Clinics and Therapeutics in other types of amyloidosis

Chairs

Laura Obici, *Amyloidosis Research and Treatment Center, University of Pavia and IRCCS Fondazione Policlinico San Matteo, Pavia, Italy*

Innovative Therapies

Chairs

Efstathios Kastiris, *National and Kapodistrian University, Athens, Greece*

Gareth Morgan, *Amyloidosis Center at Boston University School of Medicine, Boston, USA*

Peter Mollee, *Princess Alexandra Hospital, Brisbane, Queensland, Australia*

DETAILED PROGRAM – WEDNESDAY, 7TH

1:20 PM – 3:00 PM

SCIENTIFIC SESSION

Neue Aula/Main Lecture Hall

Basic research – Amyloid fibril formation including proteolysis and tissue interactions

Chairs

Matthias Schmidt, *University Ulm, Ulm, Germany*
Christoph Röcken, *University Hospital, Kiel, Germany*
Stefan Schönland, *Amyloidosis Center of the University Hospital, Heidelberg, Germany*

State-of-the-art lecture

OP060

Matthias Schmidt, Christoph Röcken, Stefan Schönland
Kinetics of the aggregation process of the human λ -III immunoglobulin light chain FOR005 involved in AL amyloidosis at atomic resolution

Tejaswini Pradhan, *Technical University, Munich, Germany*

OP061

The ex vivo cryo-EM structure of AA amyloid from a domestic short hair cat

Tim Schulte, *Gruppo San Donato, San Donato Milanese, Italy*

OP062

The interplay between protein dynamics and proteolysis in LC amyloid aggregation

Stefan Ricagno, *Università di Milano, Milano, Italy*

OP063

Time-resolved nano-spectroscopy with single-molecule sensitivity for blood-based non-immune diagnosis of amyloid diseases

Ann Tiiman, *Center for Molecular Medicine (CMM), Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden*

OP064

In vitro and in vivo effects of SerpinA1 on the modulation of transthyretin proteolysis

Maria Rosario Almeida, *Universidade do Porto, Molecular Biology Department, Porto, Portugal*

OP039

Elevated fibrosis associated biomarkers in ATTR amyloidosis patients are associated with impaired cardiovascular outcome

Selina Julia Hein, *Amyloidosis Center of the University Hospital, Heidelberg, Germany*

OP066

Dichotomy of Circulating Non-native TTR (NNTTR) Levels in Polyneuropathy and Cardiomyopathy Patients Provides a Glimpse to ATTR Tissue Specificity

Xin Jiang, *Protego Biopharma, San Diego, USA*

OP067

Heterotypic amyloid interactions and their effect on amyloid assembly
Frederic Rousseau, *VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium*

DETAILED PROGRAM – WEDNESDAY, 7TH

3:00 PM – 4:30 PM	SATELLITE SYMPOSIUM	Neue Aula/Main Lecture Hall
	Alexion: Beyond Survival: Unmet Medical Needs in AL Amyloidosis	
Chair	Vaishali Sanchorawala, <i>Amyloidosis Center at Boston University School of Medicine, Boston, USA</i>	
Introduction	Vaishali Sanchorawala	
Lecture	Looking Beyond Plasma Cell Dyscrasia in AL Amyloidosis Rodney Falk, <i>Brigham and Women's Hospital, Boston, USA</i>	
Panelists	Julian Gillmore, <i>National Amyloidosis Centre, London, United Kingdom</i> Giovanni Palladini, <i>Amyloidosis Research and Treatment Center, University of Pavia and IRCCS Fondazione Policlinico San Matteo, Pavia, Italy</i> Vaishali Sanchorawala Ashutosh Wechalekar, <i>National Amyloidosis Centre, London, United Kingdom</i>	
Lecture	Unmet Medical Needs in Managing Tissue Toxicity and Organ Dysfunction Giovanni Palladini	
Panelists	Rodney Falk, Julian Gillmore, Vaishali Sanchorawala, Ashutosh Wechalekar	
Lecture	Beyond Survival - Assessing and Monitoring Organ and Tissues Ashutosh Wechalekar	
Panelists	Rodney Falk, Julian Gillmore, Giovanni Palladini, Vaishali Sanchorawala	
Lecture	Continuing Conversation to Learn from Patient Insights Giovanni Palladini	
Panelists	Deborah Boedicker, <i>Amyloidosis Speakers Bureau, Washington, DC, USA</i> Kristen Hsu, <i>Amyloidosis Research Consortium, Newton, USA</i>	
Q&A	Vaishali Sanchorawala Rodney Falk, Giovanni Palladini, Ashutosh Wechalekar	
Close	Vaishali Sanchorawala	

DETAILED PROGRAM – WEDNESDAY, 7TH

4:30 PM – 5:00 PM **COFFEE BREAK**  New University, ground floor/2nd floor/courtyard

4:30 PM – 5:00 PM **EXHIBITION** Virtual Venue

Virtual Speaker Corner
Talk with industry partners

5:00 PM – 6:30 PM **SATELLITE SYMPOSIUM** Neue Aula/Main Lecture Hall

Alnylam: Meeting the needs of patients with hATTR amyloidosis: innovation in practice

Chair Thomas Skripuletz, *Department of Neurology, Hannover Medical School, Hannover, Germany*

Introduction Thomas Skripuletz

The origin and evolution of treatment
Thomas Skripuletz

Evolving experience with RNAi therapies in a multisystem disease – Experience of managing hATTR amyloidosis at a reference centre
Marcus Anthony Urey, *Division of Cardiology, Department of Medicine, University of California, San Diego, USA*

Evolving experience with RNAi therapies in a multisystem disease – A cardiologist’s perspective on hATTR amyloidosis
Andoni Echaniz-Laguna, *APHP, CHU de Bicêtre, Le Kremlin-Bicêtre, France*

Neurofilament Light Chain (NfL) as a biomarker in hATTR amyloidosis
Hans Nienhuis, *Amyloidosis Centre of Expertise, University Medical Center, Groningen, Netherlands*

Redefining standards of care
Laura Obici, *Amyloidosis Research and Treatment Center, University of Pavia and IRCCS Fondazione Policlinico San Matteo, Pavia, Italy*

7:00/7:30 PM
– open end

SOCIAL EVENT

“halle02” Heidelberg

Conference Dinner/Award Ceremony

The Conference Dinner is held in the largest event venue in Heidelberg located in the building of the former freight station. It offers conference participants an excellent chance to enjoy delicious food in a unique industry ambience while getting to know each other and making new connections outside the main conference environment.

Finally, the winner of the ISA 2022 presidential awards and poster awards will be presented.

The halle02 offers more than 1,500 sqm of inspiring rooms and 1,200 sqm of outdoor space for events of all kinds and is exclusively available to conference participants for this event.

How to get there?

Please see the information distributed at the congress



DETAILED PROGRAM – THURSDAY, 8TH

9:30 AM – 1:00 PM **EXHIBITION** ground floor/2ndfloor
Exhibition on-site and virtual

7:45 AM – 8:30 AM **SATELLITE SYMPOSIUM** H14
Sponsored coffee starts at 7:00 AM

Attralus: Unmet Need and Rationale for Anti-Amyloid Therapy in Systemic Amyloidosis

Chair Ashutosh Wechalekar, *National Amyloidosis Centre, London, United Kingdom*

Introduction Ashutosh Wechalekar

Lectures **Unmet need in Systemic Amyloidosis**
Morie Gertz, *Mayo Clinic, Rochester, USA*

Preclinical Rationale for Anti-Amyloid therapy
Marina Ramirez-Alvarado, *Mayo Clinic, Rochester, USA*

Review of Efficacy with Anti-Amyloid therapy
Ashutosh Wechalekar

Safety of Anti-Amyloid Approach
Arnt Kristen, *Amyloidosis Center of the University Hospital, Heidelberg, Germany*

Discussion/Close Ashutosh Wechalekar, Morie Gertz, Marina Ramirez-Alvarado, Arnt Kristen

8:30 AM – 10:15 AM **SCIENTIFIC SESSION** Neue Aula/Main Lecture Hall
Best abstracts (including late breaking)

Chairs Markus Weiler, *Amyloidosis Center Heidelberg, Germany*
Peter Mollee, *University of Queensland, Australia*

OP068 **Feasibility of a novel academic BCMA-CART (HBI0101) for the treatment of relapsed and refractory AL amyloidosis**
Moshe Gatt, *Hadassah Medical Center, Jerusalem, Israel*

DETAILED PROGRAM – THURSDAY, 8TH

- OP069 A Proteomic Atlas of Renal Amyloid Plaques Provides Insights Into Disease Pathogenesis
Charalampos Charalampous, *Mayo Clinic, Rochester, USA*
- OP070 Cryo-EM study of cardiac ATTR fibrils and structure-based development of detection probes and anti-seeding inhibitors
Lorena Saelices, *UT Southwestern, Dallas, USA*
- OP071 An European collaborative study on 476 patients with AA amyloidosis: identification and validation of survival and renal staging systems
Marco Basset, *Amyloid Research and Treatment Center, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy*
- OPLB001 Primary Results From APOLLO-B, A Phase 3 Study Of Patisiran In Patients With Transthyretin-Mediated Amyloidosis With Cardiomyopathy
Matthew Maurer, *Columbia University, New York, USA*
- OPLB002 Venetoclax targeted therapy in t(11;14) AL amyloidosis patients: a retrospective analysis from the French Amyloidosis Network
Murielle Roussel, *CHU Dupuytren, Limoges, France*
- OPLB003 Amyloidosis-related orthopedic events, low plasma transthyretin, and risk of cardiac events
Anders Moller Greve, *Rigshospitalet, Copenhagen, Denmark*

10:15 AM – 10:45 AM **COFFEE BREAK**  New University, ground floor/2nd floor/courtyard

10:45 AM – 11:45 AM **SCIENTIFIC SESSION** Neue Aula/ Main Lecture Hall
Translation – How to close the gap of basic and clinical research in systemic amyloidosis
Round Table

Chairs Stefan Schönland, *host ISA 2022, Amyloidosis Center of the University Hospital, Heidelberg, Germany*
Vittorio Bellotti, *IRCCS Fondazione Policlinico San Matteo, Pavia, Italy*

Panel of Experts Marina Ramirez-Alvarado, *Mayo Clinic, Rochester, USA*
Joost Schymkowitz, *Leuven Center for Brain & Disease Research, Leuven, Belgium*
Jonathan Wall, *University of Tennessee, Knoxville, USA*
Arnaud Jaccard, *CHU, Limoges, France*
Gunilla Westermark, *Uppsala University, Uppsala, Sweden*

DETAILED PROGRAM – THURSDAY, 8TH

11:45 AM – 12:30 PM

SOCIAL EVENT

Neue Aula/Main Lecture Hall

ISA Membership Meeting

The outgoing President, Giovanni Palladini, will report on the scientific and organisational activities of ISA during the last 2 years.

Shaji Kumar, treasurer will give his financial report.

Per Westermark, editor in chief of *Amyloid*, will give a summary on the recent developments of our journal.

Vaishali Sanchorawala, secretary, will present the election results (board and bylaws).

Stefan Schönland, President elect, will acknowledge the outgoing Board members, welcome and introduce the new Board members and give his prospects for the next 2 years.

12:30 PM – 1:00 PM

SOCIAL EVENT

Neue Aula/Main Lecture Hall

Closing Ceremony

Chairs

ISA 2022 Organizing Committee

Summary ISA 2022 Heidelberg

Bouke Hazenberg, *University Medical Center, Groningen, Netherlands*

Outlook ISA 2024

Morie Gertz, *Martha Grogan, Angela Dispenzieri, Mayo Clinic, Rochester, USA*

LUNCH BOXES



Thank you for your participation and have a safe trip back home!

POSTERS – MONDAY, 5TH

Detailed information will be provided in the abstract book which will be published on the ISA website.

Poster Presentations – Monday, 5th – 12:05 PM – 1:20 PM

- P001 Morbidity and mortality measured through “Days Alive and Out of Hospital” (DAOH) in patients with AL amyloidosis according to cardiac involvement and specific treatment.
María LOURDES POSADAS MARTINEZ
- P002 Selection of appropriate quality of life instrument to measure patient-reported outcomes in systemic light chain (AL) amyloidosis
Anita D’SOUZA
- P003 Symptom burden and quality of life in AL amyloidosis patients among recently diagnosed and long-term survivors
Anita D’SOUZA
- P004 Performance of a survival staging system incorporating sST2 in patients with light chain amyloidosis
Darae KIM
- P005 Evaluation of the Patterns Leading to Diagnosis in Patients With Amyloid Light-Chain Amyloidosis Using the Komodo Database
Julia CATINI
- P006 Healthcare resource utilization in patients with light chain amyloidosis in Europe
Efsthios KASTRITIS
- P007 Reduction of cardiac AL amyloid deposition after complete response visualized by PiB-PET imaging
Nagaaki KATOH
- P008 The impact of longitudinal strain (LS) response in patients with advanced cardiac AL amyloidosis
Joshua BOMSZTYK
- P009 CMR with T1 mapping in systemic light-chain (AL) amyloidosis: from cardiac amyloid regression to refining treatment response
Ana MARTINEZ-NAHARRO
- P010 Outcomes for patients with systemic light chain (AL) amyloidosis and Mayo stage 3B disease
Foteini THEODORAKAKOU
- P011 Finding a needle in a haystack: oligomer detection via urinary extracellular vesicles in AL light chain amyloidosis
Shawna Ann COOPER

- P012 Longitudinal testing for measurable residual disease (MRD) using multiparametric flow cytometry in patients with systemic light chain amyloidosis
Andrew STARON
- P013 Racial differences in the cytogenetic underpinnings of light chain amyloidosis
Andrew STARON
- P014 Evaluation of NT-proBNP as surrogate endpoint in AL amyloidosis: development of a platform for federated, multi-institution meta-analysis of randomized trials
Angela DISPENZIERI
- P015 Patterns of target organ amyloid deposition in patients with AL amyloidosis; role for diagnosis and prognosis
Despina FOTIOU
- P016 Diagnostic Hospitalization and Associated Costs in Patients with Amyloid Light-Chain Amyloidosis
Tiffany P. QUOCK
- P017 Atypical neurological presentation of immunoglobulin light-chain amyloidosis
Michelle PIROTTE
- P018 Characterization and outcome of patients with systemic AL amyloidosis requiring dialysis prior to initial therapy
Lilli Sophie SESTER
- P019 Beta-2-microglobulin and lactate dehydrogenase as prognostic parameters in light-chain amyloidosis
Sara OUBARI
- P020 Diagnostic value of liver stiffness as marker of hepatic amyloid deposition in systemic AL amyloidosis
Anne Floor BRUNGER
- P021 The Pattern of Organ Responses Varies in Patients with Systemic Light-chain Amyloidosis (AL) and Heart or Kidney or Heart and Kidney Involvement Who Achieve Deep Hematologic Responses
Diana ZHANG
- P022 Outcomes of patients with AL amyloidosis and end-stage renal disease requiring dialysis
Foteini THEODORAKAKOU
- P023 Identifying symptoms of AL amyloidosis in electronic health records using natural language processing, ICD codes, and manually abstracted registry data
Eli SILVERT
- P024 A revised renal staging system for long-term renal survival in patients with AL amyloidosis with renal involvement
Marco ALLINOVI

- P025 Role of subcutaneous abdominal fat tissue aspiration in the diagnosis of systemic immunoglobulin light-chain amyloidosis
David F MORENO
- P026 Functional Status and Heart Failure Quality of Life Provide Incremental Prognostic Value in Light Chain Amyloidosis
Jocelyn CANSECO NERI
- P027 Heart and autologous stem cells transplantation in AL amyloidosis.
María Adela AGUIRRE
- P028 Droxidopa for Treatment of Refractory Orthostatic Hypotension in Patients with AL Amyloidosis: A Case Series
Jorge Nicolas RUIZ LOPEZ
- P029 AL Amyloidosis – a reason to transplant MGUS phenotype?
Maximilian Johannes STEINHARDT
- P030 Daratumumab for the treatment of Relapsed/Refractory AL amyloidosis: Experience from the Amyloidosis Program of Calgary (APC)
Daniel LEVIN
- P031 Efficacy and safety of daratumumab monotherapy in newly diagnosed patients with stage 3b light chain amyloidosis: a phase 2 study by the European Myeloma Network
Efsthathios KASTRITIS
- P032 Role of Doxycycline in the treatment of patients with AL amyloidosis receiving Bortezomib-containing regimens in the frontline setting: Experience from the Amyloidosis Program of Calgary
Ellen LEWIS
- P033 Effect of the presence of t(11;14) for patients with AL amyloidosis treated with Bortezomib-containing regimens: Experiences from the Amyloidosis Program of Calgary
Ellen LEWIS
- P034 Cyclophosphamide, Bortezomib and Methylprednisolone for the treatment of AL amyloidosis: Updated report from the Amyloid Program of Calgary (APC)
Ellen LEWIS
- P035 Safety and Efficacy of Propylene Glycol-Free Melphalan in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Results of a phase II study
Michelle H. LEE
- P036 Treatment outcomes according to salvage chemotherapy modalities for relapsed/refractory AL amyloidosis
Yoon SANG EUN

- P037 Autologous stem cell transplantation in primary amyloidosis: a single centre experience
Tugrul ELVERDI
- P038 Bortezomib-based induction therapy is associated with superior hematologic responses and survival after stem cell transplantation in patients with AL amyloidosis
Joshua N GUSTINE
- P039 Venetoclax in Relapsed or Refractory AL Amyloidosis with t(11;14) and BCL2 overexpression.
Pamella PAUL
- P040 Birtamimab in Patients with Mayo Stage IV AL Amyloidosis: Rationale for Confirmatory AFFIRM-AL Phase 3 Study
Morie A. GERTZ
- P041 Assessing clinical outcomes in patients with AL amyloidosis across different criteria for hematologic complete response: Results from ANDROMEDA
Giovanni PALLADINI
- P042 Efficacy of bortezomib based regimens in elderly patients with newly diagnosed AL amyloidosis and heart failure.
David GARRIDO
- P043 Time to next treatment (TtNT) is an independent prognostic marker for outcome in newly diagnosed patients with AL amyloidosis
Despina FOTIOU
- P044 Second autologous stem cell transplantation as salvage therapy in selected patients with relapsed/progressed light-chain (AL) amyloidosis
M. Teresa CIBEIRA
- P045 IsAMYP: a phase 2 single-stage study to evaluate the efficacy of isatuximab, pomalidomide and dexamethasone, in patients with AL amyloidosis not in VGPR or better after any previous therapy.
Murielle ROUSSEL
- P046 Epidemiology of light-chain amyloidosis in Latin America: a retrospective analysis of 212 patients. Grupo Latinoamericano de Estudio del Mieloma Múltiple (GELAMM)
Erika BRULC
- P047 Timeline change of AL amyloidosis treatment response and clinical outcomes; a single-center experience from Turkey
Metban GUZEL MASTANZADE
- P048 Autologous Stem Cell Transplantation in AL amyloidosis in two centers from Latin America
Eloísa RIVA

- P049 Real-world data on safety and efficacy of upfront daratumumab-based therapy in patients with light chain (AL) amyloidosis and high plasma cell burden evaluated at 3 months
Claudia BELLOFIORE
- P050 Comparison of bortesomib-based induction regimens with other treatment modalities in patients with newly diagnosed systemic light chain amyloidosis.
Olga V. KUDYASHEVA
- P051 Autologous stem cell transplantation (ASCT) remains effective therapy for systemic immunoglobulin light chain amyloidosis (AL): Experience from a single Australian Amyloidosis Service
Tran Bing Andrew GIANG
- P052 Daratumumab, pomalidomide and dexamethasone (DPd) in relapsed/refractory light chain amyloidosis previously exposed to daratumumab (NCT04270175): Interim results
Cara A. ROSENBAUM
- P053 Functional Status and Heart Failure Quality of Life Improve Following Therapy in Light Chain Amyloid Cardiomyopathy
Jocelyn CANSECO NERI
- P054 Atrial Fibrillation Does Not Influence the Occurrence of Cerebrovascular Accidents Among Patients with Amyloidosis
Ramtej ATLURI
- P055 Morbidity and mortality measured through “Days Alive and Out of Hospital”(DAOH) in patients with amyloidosis.
María Lourdes POSADAS MARTÍNEZ
- P056 Factors associated with morbidity and mortality, measured through “Days Alive and Out of Hospital”(DAOH) in patients with AL and ATTR amyloidosis.
María Lourdes POSADAS MARTÍNEZ
- P057 Significant tricuspid regurgitation is associated with adverse outcomes in patients with transthyretin amyloidosis.
Eugenia VILLANUEVA
- P058 Prevalence of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy
Eva CABRERA ROMERO
- P059 1 Clinical findings and comorbidities in wtATTR patients with suspected amyloid neuropathy
Sasha ZIVKOVIC
- P060 Identification of wild-type transthyretin cardiac amyloidosis in patients with recent CTS surgery
Bertil LADEFOGED

- P061 Evolution of demographics of patients with transthyretin amyloid cardiomyopathy over time: implications for disease awareness strategies and future trial design
Claudio RAPEZZI
- P062 Descriptive analysis of women with transthyretin amyloid cardiomyopathy: examining the patient demographics of a growing patient population
Martha GROGAN
- P063 Assessment and Management of Older Patients with Transthyretin Amyloidosis Cardiac Amyloidosis: Geriatric Cardiology, Frailty Assessment and Beyond
Biobelemoye IRABOR
- P064 Preservation of Left Ventricle Stroke Volume in Patients with ATTRwt Cardiac Amyloidosis Treated with Selective TTR Stabiliser Tafamidis
Dariusz KORCZYK
- P065 Implementation of a machine learning model to assess transthyretin amyloid cardiomyopathy risk in an external platform
George KOUTITAS
- P066 Clinical and Socioeconomic Differences Among Patients with Transthyretin Cardiac Amyloidosis Belonging to North and South of Chicago.
Mukunthan MURTHI
- P067 Relationship of tafamidis binding site occupancy, transthyretin stabilization, and disease modification in tafamidis treated transthyretin amyloid cardiomyopathy patients
Amy T. MOODY
- P068 Diagnostic Path, Clinical Characteristics and Outcomes of Patients With ATTR Cardiomyopathy in Greece
Foteini THEODORAKAKOU
- P069 Screening for transthyretin-related amyloidosis in patients with aortic stenosis undergoing aortic valve replacement
Isabel MATTIG
- P070 Case series of the treatment journeys of patients who underwent heart transplantation for transthyretin (ATTR) cardiac amyloidosis, with subsequent confirmed orthopedic disease
Jill WALDRON
- P071 Factors Associated with Financial Toxicity in Patients with ATTR: Results From Amyloidosis Research Consortium's ATTR Treatment Affordability Patient and Caregiver Survey
Sabrina REBELLO
- P072 Characterisation of Austrian Transthyretin Amyloid Cardiomyopathy (ATTR-CM) patients enrolled in a Tafamidis (61mg) early access program
Christoph GROJER

- P073 Incidence and Risk Factors for Pacemaker Implantation in Light Chain and Transthyretin Cardiac Amyloidosis
Aldostefano PORCARI
- P074 The relationship between NT-proBNP and perception of the severity of cardiac symptoms in TTR-CA: the moderating role of anxious and depressive symptoms
Francesco CAPPELLI
- P075 Neurological symptoms of patients with transthyretin amyloidosis at first neurological presentation at the Amyloidosis Center of Lower Saxony
Janna Margaretha SIEMER
- P076 Incidence and factors associated with de novo atrial fibrillation in patients with wild-type transthyretin cardiac amyloidosis
Carlo FUMAGALLI
- P077 Quality of Life in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Inotersen
Sloan M COUGHLIN
- P078 Prospective evaluation of an applied wt-ATTR-CM machine learning model to a United States (U.S.) health system electronic health record
Ahmad FARAZ
- P079 Prognostic Value of Cardiopulmonary Exercise Testing in Patients with Transthyretin Cardiac Amyloidosis.
Francesco CAPPELLI
- P080 Tafamidis 61 mg for treatment of ATTR cardiomyopathy in daily clinical practice: an observational study
Fabian AUS DEM SIEPEN
- P081 Transthyretin Cardiac Amyloidosis (ATTR-CA) and its rising awareness: Patient characteristics and survival in the Australian context
Boyoun CHOI
- P082 Significant survival benefits with Diflunisal in patients with Transthyretin (TTR) Amyloidosis Cardiomyopathy (ATTR-CM); A retrospective analysis
Boyoun CHOI
- P083 Effect of inotersen on global longitudinal strain in transthyretin cardiac amyloidosis
Gerard T GIBLIN
- P084 Inotersen treatment in transthyretin amyloid cardiomyopathy results in early and sustained serum transthyretin knockdown
Gerard T GIBLIN
- P085 Baseline ECG characteristics in ATTR-CM
Dominic Richard PIMENTA

- P086 Real-world experience with tafamis at ceparm University hospital. Federal University of Rio de Janeiro, Brazil.
Márcia WADDINGTON-CRUZ
- P087 Real-world experience with tafamis at ceparm University hospital. Federal University of Rio de Janeiro, Brazil.
Márcia WADDINGTON-CRUZ
- P088 Neurofilament Light Chain as a Biomarker in Hereditary Transthyretin-Mediated Amyloidosis: 36-Month Data from the Patisiran Global Open-Label Extension
Emre ALDINC
- P089 Characteristics of patients with ATTR amyloidosis and the Ile107Val mutation: insights from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
Márcia WADDINGTON-CRUZ
- P090 Analysis of cardiac involvement in hereditary transthyretin amyloidosis after liver transplantation
Yohei MISUMI
- P091 4 Effect of Patisiran on Polyneuropathy and Cardiomyopathy in Patients with hATTR Amyloidosis with V122I/T60A Variants: A Phase 4 Observational Study
Francy SHU
- P092 Transthyretin amyloid polyneuropathy in mainland China: a unicentric study
Lingchao MENG
- P093 Phenotype and Clinical Outcomes of Hereditary Transthyretin Amyloidosis caused by p.Glu109Lys TTR Variant. A new endemic variant in Spain
Fernando DE FRUTOS
- P094 Comparison of disability: intradermal vasomotor nerves, intradermal sudomotor nerves, and intraepidermal sensory nerves in hereditary transthyretin amyloidosis
Konen OBAYASHI
- P095 A descriptive analysis of patients with ATTR amyloidosis and a mixed phenotype from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
Juan GONZÁLEZ-MORENO
- P096 Hereditary transthyretin amyloidosis in middle-aged and elderly patients with idiopathic polyneuropathy: a nationwide prospective study.
Guillaume FARGEOT
- P097 Characterization of patients with hereditary Transthyretin Amyloidosis in a Register Study in Germany
Helena Franziska PERNICE
- P098 Hereditary Transthyretin Amyloidosis (ATTRv) in the Middle East: a short report of two confirmed cases
Ramzi Ali TABBALAT

- P099 How occupational needs can be obtained? A Semi-Structured Interview with Hereditary Transthyretin Amyloidosis patients.
Aina Isabel GAYÁ BARROSO
- P100 A rare case of late-onset hereditary ATTR Amyloidosis with cardiac and neurologic manifestation
Vladimir CEJKA
- P101 5 Characteristics of patients with ATTR amyloidosis and the Ser77Tyr mutation: insights from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
Violaine PLANTE-BORDENEUVE
- P102 Effectiveness of patisiran following switch from tafamidis for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy
Céline LABEYRIE
- P103 Characteristics of patients with ATTR amyloidosis and the Ile68Leu mutation: insights from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
Igor DIEMBERGER
- P104 8 Characteristics of Patients With ATTR Amyloidosis and the Phe64Leu Mutation: Insights From the Transthyretin Amyloidosis Outcomes Survey (THAOS)
Marco LUIGETTI
- P105 Effect of tafamidis on disease progression in patients with non-Val30Met transthyretin amyloid polyneuropathy: a sub-study of the Transthyretin Amyloidosis Outcomes Survey (THAOS)
Alejandra GONZÁLEZ-DUARTE
- P106 Cardiological evolution of hereditary transthyretin amyloidosis (AhTTR) in patients with liver transplant
Alvaro GRAGERA MARTINEZ
- P107 Hereditary Transthyretin Amyloidosis caused by p.Ser43Asn TTR Variant. Insights and possible founder effect in Ecuador.
Fernando DE FRUTOS
- P108 A-V block as presentation of cardiac amyloid caused by conduction tissue infiltration
Cristina CHIMENTI
- P109 Comparing patient and clinician perspectives of ATTR amyloidosis: Insights from the development of the Transthyretin Amyloidosis Quality of Life (ATTR-QOL) Questionnaire
Meaghan O'CONNOR
- P110 Peritoneal dialysis is a valid treatment option in hereditary transthyretin amyloidosis
João FERNANDES

- P111 **Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP):
Electroneuromyographic findings in eighteen newly diagnosed patients**
Larissa CARVALHO
- P112 **Case series: p.Leu131Met transthyretin amyloidosis in
a Danish family: Pure cardiac phenotype?**
Andreas ANDERSEN
- P113 **20 years of symptomatic and presymptomatic genetic testing for
hereditary transthyretin amyloidosis (ATTR) in the Balearic Islands**
Eugenia CISNEROS BARROSO
- P114 **Cardiac Screening of Amyloid TTR Pathogenic Variant
Carriers: Complementary value of Echocardiographic Global
Longitudinal Strain Imaging versus Bone scintigraphy**
Sandra SANDERS-VAN WIJK
- P115 **Comparison of Amyloid Detection in the Skin and
Tenosynovium of Transthyretin Amyloidosis Patients**
Amrita DANIEL
- P116 **A rare TTR mutation determining severe cardiac and neurological amyloidosis**
Diane Xavier ÁVILA
- P117 **Lung volume restriction and abnormal cardiopulmonary response to
exercise: red warning lights in transthyretin cardiac amyloidosis**
Rishika BANYDEEN
- P118 **Evaluation and follow-up of the sudomotor function in a
cohort of ATTRv patients from a non-endemic area**
Laura MARTINEZ-VICENTE
- P119 **The Relation between African American Race, Genotype,
and Prognosis in Transthyretin Cardiac Amyloidosis**
Rola KHEDRAKI
- P120 **Pre-symptomatic genetic testing for hereditary transthyretin
amyloidosis: a 20-year single-centre experience**
Francesca BENIGNA
- P121 **Peripheral nerve and cardiac features in hATTR patients presenting
with active disease V122I, L58H and late-onset V30M in the US**
Serena ZAMPINO
- P208 **Prospective MALDI-TOF analysis of blood serum peptidome to predict
the onset and progression of hereditary transthyretin amyloidosis.**
Juan GONZÁLEZ

Poster Presentations – Tuesday, 6th – 12:05 PM – 1:15 PM

- P122 Amyloid fibril formation is suppressed by UV irradiation
Atsushi FUKUNARI
- P123 An additive destabilizing effect of two substitutions, T60I/
V122I, in heterozygous compound TTRv amyloidosis
Elena S. KLIMTCHUK
- P124 Selective recognition of human small transthyretin
aggregates by a novel monoclonal antibody
Anabela CLARO
- P125 Domain-domain interactions and dimerization of the human λ -III
immunoglobulin light chain FOR005 investigated by NMR spectroscopy
Olga Dagmara SIELUZYCKA
- P126 ALBase: an updated platform to study immunoglobulin light chain sequences
Tatiana PROKAEVA
- P127 Structure-based peptides as novel therapeutic and
detection tools in cardiac amyloidosis
Rose M. PEDRETTI
- P128 Alternative pathogenic mechanisms and novel
pharmacological approaches in gelsolin amyloidosis
Luisa DIOMEDE
- P129 Coagulative and fibrinolytic blood proteases efficiently cleave human transthyretin
(hTTR) oligomers in vitro to generate the amyloidogenic fragment hTTR(49-127)
Barbara SPOLAORE
- P130 Mechanism of Misfolding and Amyloid Aggregation of the λ 6 Light Chains
Luis DEL POZO-YAUNER
- P131 Filling the gap for transthyretin amyloidosis: biochemical and structural
studies of in vitro and in vivo assembled amyloid fibrils
Valentina MONDANI
- P132 Modulation of transthyretin aggregation: role of preformed fibrils and heparin
Guglielmo VERONA
- P133 Circulating forms of plasma transthyretin in patients with wild-
type transthyretin amyloidosis and effects of tafamidis
Chiara SANGUINETTI
- P134 Early Events of Immunoglobulin Light Chain Aggregation:
Role of the C-terminus Disulfide Bond
Valeria PIERLUISSI-RUIZ

- P135 Recommendations for Addressing the Translational Gap between Experimental and Clinical Research on Amyloid Diseases
Miriam SOLOMON
- P136 Proteolytic stability of amyloid isolated from human cataract eye lens
Chandrika MITTAL
- P137 Clusterin in Alzheimer’s disease: friend or foe?
Georgia NASI
- P138 Study of berry distinct polymorphism in ATTR amyloidosis fibrils by cryo-EM
Binh NGUYEN
- P139 Cardiac proteotoxicity is resulting from a complex interplay of several molecular properties of amyloidogenic Light Chains
Rosaria RUSSO
- P140 Assessing Immunoglobulin Light Chain Protein Stability and Stabilization by Pharmacological Chaperones Using Differential Scanning Fluorimetry
Jianying WANG
- P141 Limited cardiomyocytes’ growth response to stimulation with human plasma and phenylephrine predicts poor outcome in ATTR cardiomyopathy in an in-vitro model.
Selina Julia HEIN
- P142 When Amyloid Occupies the Bone Marrow: Are the Responses of CD138-depleted Cells from Marrows with Interstitial Amyloid Archetypal?
Ping ZHOU
- P143 Exploring the in vitro effects of light chain-induced proteotoxicity on primary human cardiovascular system cells
Paola ROGNONI
- P144 Exploring Alzheimer’s disease (AD) related human brain proteome with MALDI Imaging Mass Spectrometry in combination with shotgun proteomics
Yumiko TOYAMA
- P145 Transthyretin (hTTR) Amyloid Fibrils Trigger Plasma Clotting by Activating the Intrinsic Pathway of Blood Coagulation: Implications in Cardiac Senile Systemic Amyloidosis
Laura ACQUASALIENTE
- P146 The abstract will not be published
- P147 V30M TTR animal model displayed a downregulated expression of several chemokines in different immune cell populations
João MOREIRA
- P148 In vitro treatment of light-chain amyloidosis plasma cells to characterize response to venetoclax
Niels VAN NIEUWENHUIJZEN

- P149 **Frequent Occurrence of Fibrinogen Amyloidosis in Japanese Squirrels (*Sciurus lis*)**
Susumu IWAIDE
- P150 **Exercise suppresses mouse systemic AApoAll amyloidosis through enhancement of the p38 MAPK signaling pathway**
Cui XIAORAN
- P151 **Characterization of heterozygous ATTR Y114C amyloidosis-specific iPS cells**
Kenta OUCHI
- P152 **BiP deletion leads to decreased cell viability and antibody production in multiple myeloma cell lines**
Zainul Shoyeb HASANALI
- P153 **Age-related amyloid deposition in C57BL/6 mice: Pathological findings and characterization of the renal damage**
Ying LI
- P154 **Hemostasis dysfunction induces senile apoA2 amyloidosis in a mouse model**
G. Roussine CODO
- P155 **Endocytic inhibitory drugs protect *C. elegans* from the toxicity of amyloidogenic light chains**
Margherita ROMEO
- P156 **Is *C. elegans* a good model of β 2-microglobulin related amyloidosis?**
Giulia FARAVELLI
- P157 **Poster retracted**
- P158 **Efficient transient expression of exogenous immunoglobulin light chain (AL) full length proteins from cultured human cells**
Christopher J. DICK
- P159 **Strategies to induce amyloid light chain deposition in a transgenic mouse model**
Gemma MARTINEZ-RIVAS
- P160 **Prognostic Implication of Longitudinal Changes of Left Ventricular Global Strain after Chemotherapy in Cardiac Light Chain Amyloidosis**
Minjung BAHK
- P161 **Amyloid Valvular Heart Disease: A Look Beyond the Ventricular Walls**
Nikhil KOLLURI
- P162 **Scintigraphy Scan with planar and SPECT imaging of the chest using Technetium 99m Pyrophosphate for the assessment of AL Amyloidosis: Comparison with an ATTR cohort of patients**
Victor Hugo JIMENEZ ZEPEDA
- P163 **A kit method for direct radiolabeling the amyloid reactive peptide p5+14 with technetium-99m (99mTc) for the detection of cardiac amyloidosis by SPECT/CT imaging**
Stephen KENNEL

- P164 Quantitative changes in organ-specific amyloid load in a patient with AL amyloidosis, measured by 124I-AT-01 PET/CT imaging, correlate with serum biomarkers
Alan STUCKEY
- P165 The role of speckle tracking echocardiography in the diagnostic assessment of cardiac amyloidosis and Fabry disease
Isabel MATTIG
- P166 Assessment of Incidental Cardiac Uptake in Bone Scintigraphy across Spain. ECCINGO Study
Patricia TARILONTE
- P167 Valve disease in cardiac amyloidosis: an echocardiographic score
Alberto AIMO
- P168 Coronary flow reserve by PET 13N-Ammonia in patients with Hereditary Transthyretin Amyloidosis with and without cardiac involvement.
Aristóteles Comte DE ALENCAR NETO
- P169 Differentiation of ATTR amyloidosis based on abdominothoracic organ-specific uptake of 124I-AT-01 (124I-p5+14) assessed by PET/CT imaging
R. Eric HEIDEL
- P170 Detection of extracardiac amyloid in patients with ATTR amyloidosis by PET/CT imaging using the amyloidophilic radiotracer 124I-AT-01 (124I-p5+14)
Jonathan WALL
- P171 Myocardial stiffness evaluation using atrial kick in healthy controls and patients with cardiac amyloidosis: a pilot study
Ali SADEGHI
- P172 [99mTc]Tc-DPD Scintigraphy Associating Semi-Quantitative Methods for the Diagnosis of Cardiac Amyloidosis: Experience in an Endemic Area
Núria ORTA
- P173 Myocardial Contraction Fraction (MCF): A Simple Measure of Myocardial Shortening That is Associated with Longitudinal and Circumferential Strain in Transthyretin Cardiac Amyloidosis.
Dia SMILEY
- P174 Histological validation of cardiac 99mTc-DPD uptake in patients with cardiac transthyretin amyloidosis
Maria UNGERICHT
- P175 Is a change of the current echocardiographic red flag for left ventricular wall thickness useful in cardiac amyloidosis screening?
Maria UNGERICHT

- P176 **Prognosis of light chain amyloidosis with biopsy-proven cardiac involvement**
Matthias AURICH
- P177 **Multi-imaging characterisation of cardiac phenotype in different types of amyloidosis**
Adam IOANNOU
- P178 **Prognostic Implications of Clinical Phenotype and Severity of Cardiac Involvement in Patients Presenting with Immunoglobulin Light Chain Amyloidosis**
Aldostefano PORCARI
- P179 **Diagnostic performance characteristics of quantitative and semi-quantitative parameters of Tc99m pyrophosphate imaging for diagnosis of transthyretin (ATTR) cardiac amyloidosis: The SCAN-MP Study**
Shivda PANDEY
- P180 **DPD scintigraphy – a biomarker of microcalcifications rather than amyloid**
Ulrika THELANDER
- P181 **Prognostic Role of Echocardiographic Right Ventricular Parameters in Patients with Wild-Type ATTR Cardiac Amyloidosis**
Shravya VINNAKOTA
- P182 **False positive bone-scintigraphy in elderly hypertrophic cardiomyopathy**
Cristina CHIMENTI
- P183 **Dual-echo turbo-spin-echo and 12-echo multi-spin-echo sequences are equivalent techniques for obtaining T2-Relaxometry data in hereditary transthyretin amyloidosis**
Anysia PONCELET
- P184 **Cardiac imaging for assessing involvement in all amyloidosis patients: Experience in a single tertiary hospital**
Ana LLAMAZARES DE LA MORAL
- P185 **Phenotyping of hypertrophic cardiomyopathies using echocardiography: amyloid, Anderson-Fabry and hypertensive heart disease**
Aaisha FERKH
- P186 **Multimodality cardiac imaging in differential diagnosis of infiltrative cardiomyopathy**
Per ELDHAGEN
- P187 **Quantification of left ventricular amyloid using 124I-p5+14 (AT-01) and 18F-florbetapir positron emission tomography in AL and ATTR amyloidosis**
Olivier F. CLERC
- P188 **Changes in Left Ventricular Myocardial Composition Following Targeted Plasma Cell Therapy in Light Chain Amyloidosis: A Cardiac Magnetic Resonance Study**
Olivier F. CLERC

- P189 Evaluation of Echocardiographic Parameters for Prognostication in Patients with Systemic Light Chain Amyloidosis
Ahmet Mursel ULUSAN
- P190 Central Nervous System damage in hereditary Transthyretin Amyloidosis: A multimodal MRI study
Renan Flávio DE FRANÇA NUNES



POSTERS – TUESDAY, 6TH

Poster Presentations – Tuesday, 6th – 7:00 PM – 7:30 PM

- PLB001 Amyloid Multidisciplinary Hybrid Clinic: A novel model of care in the age of telehealth
Natasha GORRIE
- PLB002 Burden of transthyretin amyloid cardiomyopathy in patients and caregivers: interim analysis of a large, ongoing, non-interventional study
Lucia PONTI
- PLB003 Epidemiology of cardiac amyloidosis in Germany: a retrospective analysis from 2009 to 2018
Roman PFISTER
- PLB004 Ixazomib maintenance following initial therapy in patients with high-risk immunoglobulin light chain (AL) amyloidosis.
Roman PFISTER
- PLB005 **Poster retracted**
- PLB006 Mid-term analysis of the Clinical Amyloidosis Registry in Germany
Niklas FUHR
- PLB007 On bead de-glycosylation coupled with MALDI-TOF mass spectrometry provides a simple method for confirming light chain glycosylation and provides a sensitive method for residual disease detection
Hannah V. GILES
- PLB008 Real World Patient, Advocate, and Caregiver Perspectives on Amyloidosis: Awareness, Knowledge Gaps, and Psychosocial Impact
Mukund NORI
- PLB009 Renal histopathological scoring of amyloid deposits is crucial to assess disease progression in light-chain (AL) amyloidosis: a multicentre retrospective study
Marco ALIINOVI
- PLB010 Response rates to second line treatment with Daratumumab Bortezomib (Velcade) Dexamethasone (DVD) in relapsed/refractory light chain (AL) amyloidosis after initial bortezomib based regime
Joshua BOMSZTYK
- PLB011 Retrospective Cohort Study of treatment with BCL-2 inhibitor Venetoclax in relapsed or refractory AL amyloidosis
Kaya VEELKEN
- PLB012 Tafamidis medication adherence in patients with transthyretin cardiac amyloidosis (ATTR-CM) in a Japanese medical claims database
Takao KATO

- PLB013 The impact of renal histopathology on the renal outcome for newly diagnosed patients with AL amyloidosis
Tarek ASHOUR
- PLB014 The patient voice: development and results of a pilot patient experience data (PED) survey
Mukund NORI
- PLB015 The role of local complement expression in renal amyloidogenic light chain amyloidosis
Nathalie KRIEGLSTEIN
- PLB016 Transthyretin tetramer destabilization, marked by lower plasma transthyretin, is causally associated with increased risk of all-cause and cardiovascular mortality in the general population
Mette CHRISTOFFERSON
- PLB017 Two-year follow-up of the first case of systemic light chain amyloidosis treated with anti-B cell maturation antigen -CAR T cells
Aina OLIVER-CALDÉS

Poster Presentations – Wednesday, 7th – 12:05 PM – 1:20 PM

- P191 Quantitative Sensory Testing: a good tool to differentiate between an asymptomatic carrier from an early symptomatic ATTRv amyloidosis patient?
Isabel Maria CONCEIÇÃO
- P192 The Journey to Diagnosis of ATTR Amyloidosis: Burden of Early Disease
Chafic KARAM
- P193 Manifestations of chronic heart failure in patients with AL-amyloidosis and ATTR-amyloidosis. Prospective observation data.
Maria KUDRYAVTSEVA
- P194 Artificial Intelligence Enhanced Electrocardiogram: A Simple Tool to Monitor for Clinical Improvement in Cardiac Amyloidosis?
Awais MALIK
- P195 Diagnostic and therapeutic center for amyloidosis at Kumamoto University
Mitsuharu UEDA
- P196 Experiences and decision-making in confirmed and potential carriers of attr-related genetic variants
Jocelyn ASHFORD
- P197 Potential sources of error in the identification and referral of amyloidosis to a tertiary center
Lisa MENDELSON
- P198 Higher Length of Stay and Readmission Burden in Heart Failure Patients with Cardiac Amyloidosis Than Those without
Abdallah MASRI
- P199 Management and patient estimation of amyloid light-chain (al) amyloidosis in Portugal: Results from a physicians' survey
Susana SANTOS
- P200 Prevalence of pauci-symptomatic amyloid transthyretin cardiac amyloidosis in the general population
Alberto AIMO
- P201 Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies
Alberto AIMO
- P202 Finding a balance between specialist and local care: amyloidosis patient perspectives on a single-centre approach
Faye Amelia SHARPLEY

- P203 Multidisciplinary approach for the early detection of amyloid in patients who undergo carpal tunnel syndrome or lumbar stenosis surgery. Preliminary results of an ongoing study.
Núria ORTA
- P204 Artificial Intelligence-Enhanced Models To Predict Light Chain Amyloidosis From Patients With Monoclonal Gammopathy Of Undetermined Significance And Smoldering Multiple Myeloma
Eli MUCHTAR
- P205 Lumbar spinal stenosis syndrome as surrogate for transthyretin cardiac amyloidosis
Laura DE MICHIELI
- P206 Expert recommendations for improving the implementation of nuclear scintigraphy to support accurate diagnosis of cardiac amyloidosis in a non-specialist setting
Julian GILLMORE
- P207 Amyloidosis and its multifactors: A case report
Diane Xavier ÁVILA
- P208 **transferred to Monday**
- P209 Real-life evaluation of an algorithm for the diagnosis of cardiac amyloidosis
Mélanie BÉZARD
- P210 Optimal Patient Selection for Referral to Tc-99m-PYP Scanning for Transthyretin Cardiac Amyloidosis
Sarah CUDDY
- P211 Cardiac amyloidosis screening in a cohort of patients with spinal stenosis: a case series.
Pierpaolo Mattia MENNILLI
- P212 Changes in the Journey to Diagnosis of Cardiac Amyloidosis in the Past 10 Years: Results from the Amyloidosis Research Consortium's 2017 Cardiac Survey and 2022 Amyloidosis Community Survey
Sabrina REBELLO
- P213 Prognostic Value of an Artificial Intelligence Enhanced ECG Model in Cardiac Amyloidosis
Surendra DASARI
- P214 Retrospective analysis of a patient cohort with suspicion of systemic amyloidosis, finally not confirmed
Philine RITTER
- P215 Validation of Amylo-AFFECT, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosis
Mounira KHAROUBI

- P216 The landscape of amyloidosis in Switzerland: Report of the Amyloidosis Registry
Sofie BROUWERS
- P217 Low QRS voltages in cardiac amyloidosis: echocardiographic correlates and prognostic value
Alberto CIPRIANI
- P218 Clinical impact of musculoskeletal pathology in patients with transthyretin-associated amyloidosis (ATTR): retrospective analysis of the case series from our center
Andreu TRIGUERO
- P219 Early detection of hereditary amyloidosis
Ligia Rocha ANDRADE
- P220 Role of combining ai-ecg to clinical risk scores for the prediction of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction
Daniel DAVIES
- P221 Prevalence and Implications of Classic ECG Findings in a Contemporary ATTR Cohort
Genise GREEN
- P222 Prevalence of Daytime and Nighttime Central Apneas in Patients with Cardiac Amyloidosis
Francesco GENTILE
- P223 The distribution of amyloidosis diseases in Germany: National Clinical Amyloidosis Registry
Ute HEGENBART
- P224 Amyloidosis diagnoses and shifting distribution of ATTR and AL from 2019 to 2021: a German single center experience.
Timon HANSEN
- P225 Initial Experience of a Private Amyloidosis Center
Diane Xavier ÁVILA
- P226 From symptoms and signs to diagnosis – Development of a simple screening tool for hereditary transthyretin amyloidosis (AmyloScan®)
Juliane SACHAU
- P227 Determining amyloid subtype: a retrospective comparative study between a clinical, laboratory, imaging, and pathological model and mass spectrometry
Roberta Shcolnik SZOR
- P228 Cardiac amyloidosis in Latin America: Opportunities to increase disease awareness among clinicians. Findings from the AMILO-LATAM research group
Estela Isabel CARVAJAL-JUAREZ

- P229 **Quality assessment of teaching in transthyretin amyloidosis**
Bruno Vaz Kerges BUENO
- P230 **Glomerular and tubular renal function in patients with Hereditary Transthyretin Amyloidosis (ATTR)**
Moisés Dias SILVA
- P231 **Targeted sequencing of functionally selected genes in patients with wild-type transthyretin amyloidosis**
Inmaculada MORENO GÁZQUEZ
- P232 **Detection of amyloidogenic FLC in serum as a non-invasive tool to facilitate the diagnosis of AL amyloidosis**
Rivka GOLDIS
- P233 **Immunoglobulin high-throughput sequencing in Monoclonal Gammopathy of Clinical Significance (MGCS): experience of the French Amyloidosis center**
Sébastien BENDER
- P234 **Neurofilament light chain, an early biomarker for polyneuropathy in hereditary transthyretin-related (ATTRv) amyloidosis**
Milou BERENDS
- P235 **The Clusterin/von Willebrand Factor Ratio Is Significantly Lower in Marrow Plasma from AL λ -type Than from λ -isotype Monoclonal Gammopathy Patients**
Stephanie SCALIA
- P236 **A spectrum of clinical phenotypes associated with p.(Arg54Gly) TTR variant.**
Dorota ROWCZENIO
- P237 **Neurofilament light chain as early biomarker for hereditary transthyretin amyloidosis – the Swedish experience**
Malin OLSSON
- P238 **Neurofilament light chain measurement in hereditary transthyretin-related amyloidosis patients with myocardial sympathetic neuronal damage: substitution for 123I-meta-iodobenzylguanidine scintigraphy?**
Milou BERENDS
- P239 **Prevalence of variant genotype in patients with suspected cardiac ATTR amyloidosis**
Roberta MUSSINELLI
- P240 **Engraftment Syndrome After ASCT is Associated elevated IL-10 and IP-10 (CXCL10) levels**
Amer ASSAL
- P241 **Genetic modifiers in hereditary and acquired TTR amyloidosis: a genome-wide association study**
Elisa VEGEZZI

- P242 **Skin Biopsy Has A High Diagnostic Yield In Patients With Systemic Amyloidosis And Neuropathy.**
Giacomo CHIARO
- P243 **Assessing amyloid prevalence, type, and extent of burden in the ligamentum flavum of patients with spinal stenosis undergoing routine laminectomy**
Emily MARTIN
- P244 **Prevalence of Localized Amyloid in Ligamentum Flavum of Patients with Lumbar Spinal Stenosis**
Francesco MARCHI
- P245 **Definition of Bone marrow biopsy involvement in amyloidosis – proposal for reporting**
Maria M. PICKEN
- P246 **Detection of amyloid deposits in skin biopsies of patients with clinically suspected variant transthyretin amyloidosis**
Rivka GOLDIS
- P247 **Amyloid deposits are common in different spinal structures among patients with spinal stenosis referred for decompression surgery**
Navya KOTTURU
- P248 **Diagnosis and typing of pulmonary amyloidosis: A series of cases**
Paola CASTILLO
- P249 **Concurrent light chain amyloidosis and proximal tubulopathy: insights into different aggregation behavior.**
Simone FEURSTEIN
- P250 **Clinicopathological analyses of an autopsied case with hereditary ATTR amyloidosis 22 years after liver transplantation**
Shiori YAMAKAWA
- P251 **Clinical ApoA-IV amyloid is associated with fibrillogenic signal sequence**
Diana CANETTI
- P252 **Removal of Cardiac AL-Amyloid leads to Cardiomyocyte Positive Remodeling and Restrictive Pattern Reversal**
Cristina CHIMENTI
- P253 **Degree of transthyretin fragmentation in ATTR amyloidosis tissues**
Francesca LAVATELLI
- P254 **Glomerular proteomics – unmasking sub-clinical amyloid or false positive?**
Janet GILBERTSON
- P255 **Complement in amyloidosis – immunohistochemical verification of activation of the complement system in renal light-chain amyloidosis**
Helene MÜHLE

- P256 Trends in renal amyloidosis over a 30-year period: Data from the Norwegian Kidney Biopsy Registry 1988 – 2017
Hilde Jæger VASSTRAND
- P257 Clinical and Morphological Phenotypes of AL and ATTR Amyloidosis Detected via Gastrointestinal Biopsies
Catherine E. HAGEN
- P258 Amyloid deposition in granuloma of tuberculosis patients: A single-center pilot study
Shreya GHOSH
- P259 The role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: results of a prospective study in 332 patients
Martina NANCI
- P260 Managing patients with carpal tunnel syndrome and positive congo red stain: a work in progress
Ankita TANDON
- P261 RNA-sequencing reveals similarity of AL amyloidosis and MGUS aberrant cells along with several potential target genes
Zuzana CHYRA
- P262 Presentation and outcome of patients with coexisting cardiac AL and ATTR amyloidosis
Marco BASSET
- P263 Validation of a mouse anti-human Serum Amyloid A antibody immunohistological test for diagnostic clinical practice.
Nicola Amy BOTCHER
- P264 Patients with two different systemic amyloidoses – a case series
Justina DAMJANOVIC-VESTERLUND
- P265 The use of abdominal fat aspiration biopsy to quantify the amyloid burden during long-term follow-up of patients with AA amyloidosis
Norbert BLANK
- P266 Renal amyloidosis in people who inject drugs in Oslo, Norway.
Helga GUDMUNSDOTTIR
- P267 Properties of generic monoclonal AA antibodies for classifying most vertebrate AA amyloidoses, and as probes for innate functions of SAA
Reinhold Paul LINKE
- P268 SARS-Cov2 infection in AA amyloidosis: a high rate of mortality
Rim BOURGUIBA
- P269 Clinicopathological characteristics of a Japanese case with fibrinogen A α -chain amyloidosis
Toshiya NOMURA

- P270 Hereditary Gelsolin amyloidosis: Clinical features from a large cohort in the US
Lisa MENDELSON
- P271 Siblings with a novel type of amyloid neuropathy, hereditary A β 2M amyloid neuropathy: Report of the second family in the world
Nagaaki KATOH
- P272 Apolipoprotein A-IV amyloidosis in a Cotton-top tamarin (*Saguinus oedipus*)
Tomoaki MURAKAMI
- P273 Histological and proteomic analyses of semenogelin 1 amyloid deposits
Masayoshi TASAKI
- P274 Mass spectrometry-based proteomic analysis of adsorbed molecules related with dialysis-related amyloidosis in hexadecyl-immobilized cellulose beads.
Suguru YAMAMOTO
- P275 Echocardiographic findings in subjects with an amyloidogenic apolipoprotein A1 mutation
Daniela TOMASONI
- P276 Iatrogenic cerebral amyloid angiopathy
Jan Christoph PURRUCKER
- P277 Fibrinogen A alpha-chain amyloidosis journey: dialysis and kidney transplantation interface
José Pedro ESCALEIRA
- P278 NNC6019-0001, a humanized monoclonal antibody, in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): rationale and study design of a phase 2, randomized, placebo-controlled trial
Matthew MAURER
- P279 Efficacy and safety of belantamab mafodotin monotherapy in patients with relapsed or refractory light chain amyloidosis: a phase 2 study by the European Myeloma Network
Efsthios KASTRITIS
- P280 Glavonoid, a possible prophylactic supplement for ATTR amyloidosis
Hiroaki MATSUSHITA
- P281 Safety and tolerability of CAEL-101, an anti-amyloid monoclonal antibody, combined with anti-plasma cell dyscrasia therapy in patients with light-chain (AL) amyloidosis: results from a phase 2 study
Cristina QUARTA
- P282 Preclinical characterization of AT-04, a pan-amyloid-binding Fc domain-peptide fusion, to serve as an opsonin for macrophage-mediated clearance of amyloid deposits
J. Steve FOSTER

- P283 Characteristics of patients with hereditary transthyretin amyloidosis-polyneuropathy (ATTRv-PN) in NEURO-TTRtransform, a phase 3 study of eplontersen
Markus WEILER
- P284 AT-03 Demonstrated Pan-amyloid Binding and Stimulated the Removal of Amyloid Deposits through Macrophage-Mediated Phagocytosis
Christophe SIRAC
- P285 Design and Evaluation of shRNA Polyplex with Cyclodextrin-modified Dendrimer for Treatment of Systemic and Localized Amyloidosis
Masamichi INOUE
- P286 Rational design of AML therapeutic agents that specifically bind and clear diverse amyloid aggregates
Karine GORAJ
- P287 Development of new antibody-based therapies against systemic amyloidoses
Janett KÖPPEN
- P288 Exploring the inhibitory effect of a natural product, Siderol, on the aggregation of Amyloid- β peptide.
Aikaterini Evangelia RIZOU
- P289 A Phase 1/2 Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, PK and Efficacy of ZN-d5, a Novel BCL-2 Inhibitor, for Treatment of Subjects with Relapsed/Refractory AL Amyloidosis
Efsthathios KASTRITIS
- P290 Venetoclax and simvastatin synergize to enhance responses in AL amyloidosis harboring t(11;14)
Hashim MANN
- P291 Exploiting existing drugs against Alzheimer's disease: a protein-drug interaction network approach
Avgi Elena APOSTOLAKOU
- P292 Inhibition of antibody light chain amyloid formation by small molecules
Gareth J. MORGAN
- P293 Cell-Penetrating Peptides with Unexpected Anti-Amyloid Properties
Sebastian WÄRMLÄNDER
- P294 Discovering Potent Small Molecule Kinetic Stabilizers of Amyloidogenic Immunoglobulin Light Chains
Nicholas L. YAN
- P295 Long Term Survival of AL Patients Treated on Phase 1 trial of CAEL-101
Divaya BHUTANI

SPONSORS

PLATIN SPONSORS



Alexion

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases. As a leader in rare diseases for nearly 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions.



Alnylam

Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. For more information visit www.alnylam.com.



Astra/Ionis

Please join our expert faculty for an in-depth discussion of the pathophysiology, diagnosis, and multidisciplinary management of patients with ATTR-PN, ATTR-CM, and mixed-phenotype ATTR from the neurologist's and cardiologist's perspectives.



Janssen

Join us for this Janssen-sponsored live and interactive satellite symposium entitled **Navigating the patient journey in AL amyloidosis: a multidisciplinary approach** being held from 16.30 – 18.00 CEST on Monday 5 September 2022.



Pfizer

Pfizer is committed to transform what it means to live with a rare disease. ATTR amyloidosis is a complex, underdiagnosed disease, with poor prognosis if left untreated. Our symposium provides a roadmap for improving the outcomes of this patients.

GOLD SPONSORS

BridgeBio

Hope through rigorous science



Prothena

Prothena is a late-stage clinical biotechnology company pioneering novel medicines for diseases caused by misfolded proteins.



SILVER SPONSORS



BRONZE SPONSORS



BIOTEC-LEVEL



SPONSORS

TRANSPARENCY REQUIREMENTS

The conference is financed with the support of sponsors, who thus also receive a promotional value. The representation of the companies at the congress is done via logos up to exhibition stands of different sizes on site. We provide information about the financial support of the industry in coordination with the companies. The contents of this event are designed to be product and service neutral.

COMPANY	EXTENT OF SUPPORT	CONDITION
Platin		
Alexion/Astra Zeneca	140 000 €	Support congress, exhibition, symposium, advertisements
Alnylam	140 000 €	Support congress, exhibition, symposium, advertisements
Ionis/Astra Zeneca	140 000 €	Support congress, exhibition, symposium, advertisements
Janssen	140 000 €	Support congress, exhibition, symposium, advertisements
Pfizer	140 000 €	Support congress, exhibition, symposium, advertisements
Gold		
Bridgebio	90 000 €	Support congress, exhibition, symposium, advertisements
Prothena	90 000 €	Support congress, exhibition, symposium, advertisements
Silver		
Attralus	50 000 €	Support congress, exhibition, symposium, logo
Sobi	50 000 €	Support congress, exhibition, symposium, logo
Bronze		
Abbvie	15 000 €	Support congress, exhibition, logo
BindingSite	15 000 €	Support congress, exhibition, logo
BMS	15 000 €	Support congress, exhibition, logo
GSK	15 000 €	Support congress, exhibition, logo
Intellia	15 000 €	Support congress, logo
Protego	15 000 €	Support congress, exhibition, logo
Sanofi	15 000 €	Support congress, exhibition, logo
Zentalis	15 000 €	Support congress, exhibition, logo
Biotec-Level		
Neurimmune	5 000 €	Support congress, exhibition, logo
Life Molecular Imaging	5 000 €	Support congress, exhibition, logo

SAVE THE DATE

The 2024 International Symposium
on Amyloidosis will be held at

**Mayo Clinic in Rochester
Minnesota, USA
on June 9 – 13, 2024**

